

*Application  
for  
United States Letters Patent*

To all whom it may concern:

Be it known that **Kenneth A. Jones, Mary W. Walker, Joseph Tamm, Theresa A. Brancheck,  
and Christophe P.G. Gerald**

have invented certain new and useful improvements in

**Chimeric G Proteins And Uses Thereof**

of which the following is a full, clear and exact description.

**CHIMERIC G PROTEINS AND USES THEREOF**

5

**BACKGROUND OF THE INVENTION**

10 Throughout this application various publications are referred to by partial citations within parenthesis. Full citations for these publications may be found at the end of the specification immediately preceding the claims. The disclosures of these publications, in their entireties, are hereby incorporated by  
15 reference into this application in order to more fully describe the state of the art to which the invention pertains.

**Therapeutic importance of G protein-coupled receptors**

20 Intercellular communication in multicellular organisms relies on numerous signal transduction pathways that allow chemical messages to be sensed extracellularly and converted into intracellular  
25 responses. One of the most ancient and well-diversified pathways uses G protein-coupled receptors (GPCRs) as the chemical sensor. GPCRs comprise a large family of transmembrane signaling proteins that are key to a variety of cellular activities including  
30 phototransduction, olfaction, neurotransmission, and endocrine function.

There are currently about 300 molecularly identified GPCRs and this number is rapidly growing. Estimates  
35 based on genomes that have been entirely sequenced suggest that there may be more than 1000 GPCRs in humans. The fact that a large proportion of prescribed drugs act on GPCRs coupled with the evidence of a large reserve of undiscovered genes

suggests that these proteins will continue to be major targets for drug discovery for the foreseeable future.

5     Signaling pathways used by GPCRs

GPCRs mediate diverse cellular responses to external stimuli through their interaction with a single class of proteins known as heterotrimeric G proteins (G proteins). These proteins are composed functionally of two subunits, an  $\alpha$  subunit that possesses GPCR-recognition and GTP-binding domains, and a dimer formed by  $\beta$  and  $\gamma$  subunits (Bourne, 1997; Lambright et al., 1996). Stimulated by agonist binding, GPCRs induce a conformational change in the G protein that facilitates the exchange of GDP for GTP bound to the  $\alpha$  subunit. In the GTP-bound state, the  $\alpha$  subunit is free to dissociate from the  $\beta\gamma$  dimer, permitting the two subunits to independently interact with a number of membrane-bound effector proteins including enzymes and ion channels.

To date, there are 17  $G\alpha$  subunits that have been cloned (Simon et al., 1991). These fall broadly into four classes: those that activate phospholipase C ( $G\alpha_q$ ,  $G\alpha_{11}$ ,  $G\alpha_{14}$ ,  $G\alpha_{15}$ , and  $G\alpha_{16}$ ), those that stimulate adenylate cyclase ( $G\alpha_s$  and isoforms), those that mediate inhibition of adenylate cyclase and also permit interaction with a variety of other effectors through release of  $\beta\gamma$  subunits ( $G\alpha_i$  and  $G\alpha_o$  isoforms), and finally  $G\alpha_{12}$  and  $G\alpha_{13}$  whose regulatory functions are less well understood. By detecting and discriminating among structural features of both  $\beta\gamma$  and  $G\alpha$ , the individual GPCR activates only a subset of available G proteins (Bourne, 1997).

The "funneling" of signaling events through specific classes of G proteins has had important consequences for the design of assays to test the functional status of a given receptor. For example, receptors that couple strongly to  $G\alpha_q$ , such as  $\alpha_{1A}$ -adrenoceptors, 5-HT<sub>2c</sub> receptors, or H1 histamine receptors, activate phospholipase C isoforms, initiating a rise in inositol phosphates (IP3) and a release of calcium from intracellular stores. Specific assays have been developed to measure the release of these signaling molecules. Likewise, other assays have been developed for measuring accumulation or depletion of cAMP (from stimulation or inhibition of adenylate cyclase) due to stimulation of receptors coupling either to  $G\alpha_s$  or  $G\alpha_i$ , respectively. A myriad of other assays have been elaborated that measure ion channel, GPTyS binding, MAP kinase, or transcriptional activities. In further elaborations of these methods, artificial "reporter genes" are used to provide a simplified endpoint initiated by some of the above cellular responses.

#### Ligand identification for GPCR "orphan" receptors

The discovery of new GPCRs has outpaced the identification of new natural ligands, leading to a growing list of "orphan" G protein-coupled receptors whose ligand is unknown. Identifying the ligands for these orphan receptors is critical for determining their biological importance and will permit investigations into receptor pharmacology and drug design. While it is possible to identify ligands by binding, such assays depend upon the availability of high affinity radiolabeled ligands, and often on high levels of expression of the cloned receptor. On the

other hand, functional activity can be elicited using unmodified, naturally occurring ligands applied to cells expressing moderate densities of receptor. The primary disadvantage of the functional approach is not knowing which class of G protein will couple efficiently to the orphan receptor. Although much progress has been made toward identifying motifs within the intracellular portions of GPCRs that bind G proteins, currently it is not possible to predict which class of G protein will couple to a given receptor. This uncertainty requires the employment of multiple functional assays for each orphan receptor in order to cover all possible signal transduction pathways. The availability of a single, genetically modified G protein that could couple universally to the vast majority of GPCRs would be an extremely useful tool for the study of orphan receptors and for the development of new therapeutic agents targeting GPCRs.

#### "Promiscuous" G proteins and modified G proteins

The design of a universal functional assay for all GPCRs is a highly sought after goal for the pharmaceutical industry. Such an assay would eliminate the need to run multiple parallel assays for each receptor. Work on the  $G\alpha_{16}$  subunit (Offermans and Simon, 1995) showed that a single G protein can "route" receptors that normally couple to inhibition of adenylate cyclase to stimulation of inositol phosphate production (Offermanns and Simon, 1995). Such a system can take advantage of instrumentation that detects  $Ca^{++}$  mobilization via fluorescent dyes in a multiwell plate format suitable for mass screening of compound libraries. Unfortunately, while heterologous expression systems

incorporating  $G\alpha_{16}$  are amenable to mass screening, there are a significant number of GPCRs that do not couple well to this G protein, reducing its general utility for screening orphan receptors.

5

Studies of the three dimensional structure of native G proteins (Lambright et al., 1996) and the functional activities of chimeric G proteins (see for review, Milligan and Rees, 1999) point to two regions of the  $G\alpha$  subunit that are involved in receptor recognition. Conklin and co-workers (Conklin et al., 1993) provided experimental evidence that the extreme C-terminal regions of  $G\alpha_q$ ,  $G\alpha_s$ , and  $G\alpha_{i2}$  are important for directing targeting to the receptor. For example, replacing the last five amino acids of  $G\alpha_q$  with the corresponding amino acids from  $G\alpha_{i2}$ , permitted three receptors, which normally couple to  $G\alpha_{i/o}$ , to stimulate phospholipase C (PLC). Similarly, replacing with the terminal five amino acids of  $G\alpha_s$ , permitted stimulation of PLC by the vasopressin V2 receptor, which normally activates adenylate cyclase (Conklin et al., 1996). Other experiments, in which  $G\alpha_s$  was altered by the C-terminal amino acids of  $G\alpha_q$ , demonstrated the generality of the finding that a given G protein can be re-directed by replacing the C-terminus of a given  $G\alpha$  "backbone" with the appropriate C-terminus of another  $G\alpha$  subunit (see for review, Milligan and Rees, 1999). Thus, the C-terminus of  $G\alpha$  is one important determinant for GPCR recognition and may be modified to channel responses from the preferred signaling pathway to another one that would be amenable to automation.

The N-terminus of  $G\alpha$  is also involved in directing G protein to a target receptor, but the specificity for

35

this is much less well understood. Kostenis and co-workers (Kostenis et al., 1997; Kostenis et al., 1998) noted that the N-termini of  $G\alpha_q$  and  $G\alpha_{11}$  are unique in that they contain a six amino acid extension not found in other  $G\alpha$  subunits. Deletion of this extension permitted GPCRs that do not normally couple to wild-type  $G\alpha_q$  to productively couple to the mutant and activate PLC. Although N-terminal deletion mutants of  $G\alpha_q$  improve coupling to  $G\alpha_{i/o}$ -coupled receptors, the amplitude of second messenger response in many instances is low and not sufficient for mass screening applications.

#### Use of ancestral G proteins

Sequence analysis of  $G\alpha$  genes from organisms spanning multiple phyla suggests the existence of a primordial  $G\alpha$  ancestor (Wilkie and Yokoyama, 1994; Seack et al., 1998; Suga et al., 1999; Figure 1). Lower organisms having less elaborate second messenger pathways and effector protein targets might harbor  $G\alpha$  homologues that are closer in structure to the ancestral protein. Further, these proteins may have the capacity to interact promiscuously with a wide variety of GPCRs because they lack structural motifs that subsequently evolved for the recognition of specific receptor subtypes. For example, in the search for primitive G proteins we noted that all invertebrate species, including *Caenorhabditis elegans* (*C. elegans*) and *Drosophila melanogaster* (*D. melanogaster*), lack the first six amino acids corresponding to the N-terminus of mammalian  $G\alpha_q$  subunits. The use of  $G\alpha$  subunits from species that appear evolutionarily early on the phylogenetic tree offers an approach to universal coupling that has not been previously described.

*C. elegans* is an attractive organism because its genome has been completely sequenced (The *C. elegans* Sequencing Consortium, 1998) and because, as a pseudocoelomate, it branches early in the phylogenetic tree (Keeton, 1980). *C. elegans* contains only a single homologue from each of the four major  $G\alpha$  families:  $G\alpha_q$ ,  $G\alpha_i$ ,  $G\alpha_s$ , and  $G\alpha_{12}$  (Jansen et al., 1999). This contrasts with mammals which have multiple isoforms within each of these families and, at the other phylogenetic extreme, yeast which has only two  $G\alpha$  subunits (Simon et al., 1991). The single  $G\alpha_q$  subunit of *C. elegans* may, therefore, couple to a wider range of GPCRs than any of its mammalian homologues. When combined with specific C-terminal tails derived from mammalian non- $G\alpha_q$  subunits, the resulting chimeric G proteins may be further enhanced in their ability to efficiently couple to mammalian GPCRs.

This application describes the use of  $G\alpha_q$  subunits obtained from invertebrate organisms, using *C. elegans* and *D. melanogaster* as examples, as "backbones" for the construction of chimeras. One chimera in particular, composed of *C. elegans*  $G\alpha_q$  ( $cG\alpha_q$ ) and modified to contain on its C-terminus the five amino acids of human  $G\alpha_z$  ( $hG\alpha_z$ ), exhibits surprisingly robust coupling to 78% of a large sample of cloned GPCRs. Further described are uses for this  $G\alpha$  chimera, and others, related to the identification of ligands for orphan GPCRs and for high-throughput screening of chemical compounds in functional assays.

**SUMMARY OF THE INVENTION**

The present invention provides an isolated nucleic acid encoding a chimeric G protein, wherein the chimeric G protein comprises an invertebrate G $\alpha$ q G protein from which at least five, but not more than twenty-one, contiguous amino acids beginning with the C-terminal amino acid have been deleted and replaced by a number of contiguous amino acids present in a vertebrate G protein beginning with the C-terminal amino acid of such vertebrate G protein, wherein such number equals the number of amino acids deleted or varies therefrom by no more than five amino acids, provided that at least five of the C-terminal amino acids of the chimeric G protein are present at the C-terminus of such vertebrate G protein.

The invention also provides a process for determining whether a chemical compound is a mammalian G protein-coupled receptor agonist which comprises contacting cells transfected with and expressing DNA encoding a chimeric G protein and expressing DNA encoding a mammalian G protein-coupled receptor, with the compound under conditions permitting the activation of the mammalian G protein-coupled receptor, and detecting an increase in mammalian G protein-coupled receptor activity, so as to thereby determine whether the compound is a mammalian G protein-coupled receptor agonist.

The invention further provides a process for determining whether a chemical compound is a mammalian G protein-coupled receptor agonist which comprises contacting a membrane preparation from cells transfected with and expressing DNA encoding a chimeric G protein and expressing DNA encoding a

mammalian G protein-coupled receptor, with the compound under conditions permitting the activation of the mammalian G protein-coupled receptor, and detecting an increase in mammalian G protein-coupled receptor activity, so as to thereby determine whether the compound is a mammalian G protein-coupled receptor agonist.

In addition, the invention provides a process for determining whether a chemical compound is a mammalian G protein-coupled receptor antagonist which comprises contacting cells transfected with and expressing DNA encoding a chimeric G protein and expressing DNA encoding a mammalian G protein-coupled receptor, with the compound in the presence of a known mammalian G protein-coupled receptor agonist, under conditions permitting the activation of the mammalian G protein-coupled receptor, and detecting a decrease in mammalian G protein-coupled receptor activity, so as to thereby determine whether the compound is a mammalian G protein-coupled receptor antagonist.

The invention further provides a process for determining whether a chemical compound is a mammalian G protein-coupled receptor antagonist which comprises contacting a membrane preparation from cells transfected with and expressing DNA encoding a chimeric G protein and expressing DNA encoding a mammalian G protein-coupled receptor, with the compound in the presence of a known mammalian G protein-coupled receptor agonist, under conditions permitting the activation of the mammalian G protein-coupled receptor, and detecting a decrease in mammalian G protein-coupled receptor activity, so as

to thereby determine whether the compound is a mammalian G protein-coupled receptor antagonist.

5 The invention also provides a process for determining whether a chemical compound specifically binds to and activates a mammalian G protein-coupled receptor, which comprises contacting cells producing a second messenger response, expressing the DNA encoding the mammalian G protein-coupled receptor, and expressing  
10 the DNA encoding a chimeric G protein, wherein such cells do not normally express the DNA encoding the chimeric G protein, with the chemical compound under conditions suitable for activation of the mammalian G protein-coupled receptor, and measuring the second  
15 messenger response in the presence and in the absence of the chemical compound, a change in the second messenger response in the presence of the chemical compound indicating that the compound activates the mammalian G protein-coupled receptor.

20 In addition, the invention provides a process for determining whether a chemical compound specifically binds to and inhibits activation of a mammalian G protein-coupled receptor, which comprises separately  
25 contacting cells producing a second messenger response, expressing the DNA encoding the mammalian G protein-coupled receptor, and expressing the DNA encoding a chimeric G protein, wherein such cells do not normally express the DNA encoding the chimeric G  
30 protein, with both the chemical compound and a second chemical compound known to activate the mammalian G protein-coupled receptor, and with only the second chemical compound, under conditions suitable for activation of the mammalian G protein-coupled  
35 receptor, and measuring the second messenger response in the presence of only the second chemical compound

and in the presence of both the second chemical compound and the chemical compound, a smaller change in the second messenger response in the presence of both the chemical compound and the second chemical compound than in the presence of only the second chemical compound indicating that the chemical compound inhibits activation of the mammalian G protein-coupled receptor.

The invention further provides a process of screening a plurality of chemical compounds not known to activate a mammalian G protein-coupled receptor to identify a compound which activates the mammalian G protein-coupled receptor which comprises:

- (a) contacting cells transfected with and expressing DNA encoding a chimeric G protein and expressing DNA encoding a mammalian G protein-coupled receptor with the plurality of compounds not known to activate the mammalian G protein-coupled receptor, under conditions permitting activation of the mammalian G protein-coupled receptor;
- (b) determining whether the activity of the mammalian G protein-coupled receptor is increased in the presence of one or more of the compounds; and if so
- (c) separately determining whether the activation of the mammalian G protein-coupled receptor is increased by any compound included in the plurality of compounds, so as to thereby identify each compound which activates the mammalian G protein-coupled receptor.

The invention still further provides a process of screening a plurality of chemical compounds not known to inhibit the activation of a mammalian G protein-coupled receptor to identify a compound which inhibits the activation of the mammalian G protein-coupled receptor, which comprises:

- (a) contacting cells transfected with and expressing DNA encoding a chimeric G protein and expressing DNA encoding a mammalian G protein-coupled receptor with the plurality of compounds in the presence of a known mammalian G protein-coupled receptor agonist, under conditions permitting activation of the mammalian G protein-coupled receptor;
- (b) determining whether the extent or amount of activation of the mammalian G protein-coupled receptor is reduced in the presence of one or more of the compounds, relative to the extent or amount of activation of the mammalian G protein-coupled receptor in the absence of such one or more compounds; and if so
- (c) separately determining whether each such compound inhibits activation of the mammalian G protein-coupled receptor for each compound included in the plurality of compounds, so as to thereby identify any compound included in such plurality of compounds which inhibits the activation of the mammalian G protein-coupled receptor.

The invention also provides a process for determining whether a chemical compound is a mammalian G protein-coupled receptor agonist, which comprises separately

contacting membrane preparations from cells transfected with and expressing DNA encoding a chimeric G protein and expressing DNA encoding a mammalian G protein-coupled receptor with both the compound and [<sup>35</sup>S]GTPγS, and with only [<sup>35</sup>S]GTPγS, under conditions permitting the activation of the mammalian G protein-coupled receptor, and detecting [<sup>35</sup>S]GTPγS binding to the membrane preparation and an increase in [<sup>35</sup>S]GTPγS binding in the presence of the compound indicating that the chemical compound activates the mammalian G protein-coupled receptor.

In addition, the invention provides a process for determining whether a chemical compound is a mammalian G protein-coupled receptor antagonist which comprises separately contacting membrane preparations from cells transfected with and expressing DNA encoding a chimeric G protein and expressing DNA encoding a mammalian G protein-coupled receptor with the chemical compound, [<sup>35</sup>S]GTPγS, and a second chemical compound known to activate the mammalian G protein-coupled receptor, with [<sup>35</sup>S]GTPγS and only the second compound, and with [<sup>35</sup>S]GTPγS alone, under conditions permitting the activation of the mammalian G protein-coupled receptor, detecting [<sup>35</sup>S]GTPγS binding to each membrane preparation, comparing the increase in [<sup>35</sup>S]GTPγS binding in the presence of the compound and the second compound relative to the binding of [<sup>35</sup>S]GTPγS alone to the increase in [<sup>35</sup>S]GTPγS binding in the presence of the second chemical compound relative to the binding of [<sup>35</sup>S]GTPγS alone, and detecting a smaller increase in [<sup>35</sup>S]GTPγS binding in the presence of the compound and the second compound indicating that the compound is a mammalian G protein-coupled receptor antagonist.

The invention further provides a process for determining whether a chemical compound is a mammalian G protein-coupled receptor agonist, which comprises contacting cells transfected with and expressing DNA encoding a chimeric G protein and expressing DNA encoding a mammalian G protein-coupled receptor with a compound, under conditions permitting the activation of the mammalian G protein-coupled receptor, and detecting changes in receptor active state conformation as manifested by changes in receptor/G protein heterotrimer association/dissociation in the presence of the compound indicating that the chemical compound activates the mammalian G protein-coupled receptor.

The inventions still further provides a process for determining whether a chemical compound is a mammalian G protein-coupled receptor antagonist which comprises separately contacting cells transfected with and expressing DNA encoding a chimeric G protein and expressing DNA encoding a mammalian G protein-coupled receptor with the chemical compound in the presence of a known mammalian G protein-coupled receptor agonist, under conditions permitting the activation of the mammalian G protein-coupled receptor, and detecting changes in receptor active state conformation as manifested by changes in receptor/G protein heterotrimer association/dissociation in the presence of the compound indicating that the compound is a mammalian G protein-coupled receptor antagonist.

The invention also provides a process for identifying a chemical compound which specifically binds to a mammalian G protein-coupled receptor which comprises

contacting cells transfected with and expressing DNA encoding a chimeric G protein and expressing DNA encoding a mammalian G protein-coupled receptor, wherein such cells do not normally express the DNA encoding the chimeric G protein, with the compound under conditions suitable for binding, and detecting specific binding of the chemical compound to the mammalian G protein-coupled receptor.

The invention further provides a process for identifying a chemical compound which specifically binds to a mammalian G protein-coupled receptor which comprises contacting a membrane preparation from cells transfected with and expressing DNA encoding a chimeric G protein and expressing DNA encoding a mammalian G protein-coupled receptor, wherein such cells do not normally express the DNA encoding the chimeric G protein, with the compound under conditions suitable for binding, and detecting specific binding of the chemical compound to the mammalian G protein-coupled receptor.

In addition, the invention provides a process involving competitive binding for identifying a chemical compound which specifically binds to a mammalian G protein-coupled receptor which comprises separately contacting cells transfected with and expressing DNA encoding a chimeric G protein and expressing DNA encoding a mammalian G protein-coupled receptor, wherein such cells do not normally express the DNA encoding the chimeric G protein, with both the chemical compound and a second chemical compound known to bind to the mammalian G protein-coupled receptor, and with only the second chemical compound, under conditions suitable for binding of both compounds, and detecting specific binding of the

chemical compound to the mammalian G protein-coupled receptor, a decrease in the binding of the second chemical compound to the mammalian G protein-coupled receptor in the presence of the chemical compound indicating that the chemical compound binds to the mammalian G protein-coupled receptor.

The invention further provides a process involving competitive binding for identifying a chemical compound which specifically binds to a mammalian G protein-coupled receptor which comprises separately contacting a membrane preparation from cells transfected with and expressing DNA encoding a chimeric G protein and expressing DNA encoding a mammalian G protein-coupled receptor, wherein such cells do not normally express the DNA encoding the chimeric G protein, with both the chemical compound and a second chemical compound known to bind to the receptor, and with only the second chemical compound, under conditions suitable for binding of both compounds, and detecting specific binding of the chemical compound to the mammalian G protein-coupled receptor, a decrease in the binding of the second chemical compound to the mammalian G protein-coupled receptor in the presence of the chemical compound indicating that the chemical compound binds to the mammalian G protein-coupled receptor.

The invention also provides a process of screening a plurality of chemical compounds not known to bind to a mammalian G protein-coupled receptor to identify a compound which specifically binds to the mammalian G protein-coupled receptor, which comprises

(a) contacting cells transfected with and expressing DNA encoding a chimeric G protein and expressing

DNA encoding a mammalian G protein-coupled receptor with a compound known to bind specifically to the mammalian G protein-coupled receptor;

5

(b) contacting the cells of step (a) with the plurality of compounds not known to bind specifically to the mammalian G protein-coupled receptor, under conditions permitting binding of compounds known to bind to the mammalian G protein-coupled receptor;

10

(c) determining whether the binding of the compound known to bind to the mammalian G protein-coupled receptor is reduced in the presence of the plurality of compounds, relative to the binding of the compound in the absence of the plurality of compounds; and if so

15

(d) separately determining the binding to the mammalian G protein-coupled receptor of each compound included in the plurality of compounds, so as to thereby identify any compound included therein which specifically binds to the mammalian G protein-coupled receptor.

20

25

The invention further provides a process of screening a plurality of chemical compounds not known to bind to a mammalian G protein-coupled receptor to identify a compound which specifically binds to the mammalian G protein-coupled receptor, which comprises

30

(a) contacting a membrane preparation from cells transfected with and expressing DNA encoding a chimeric G protein and expressing DNA encoding a mammalian G protein-coupled receptor with the

35

plurality of compounds not known to bind specifically to the mammalian G protein-coupled receptor under conditions permitting binding of compounds known to bind to the mammalian G protein-coupled receptor;

(b) determining whether the binding of a compound known to bind to the mammalian G protein-coupled receptor is reduced in the presence of the plurality of compounds, relative to the binding of the compound in the absence of the plurality of compounds; and if so

(c) separately determining the binding to the mammalian G protein-coupled receptor of each compound included in the plurality of compounds, so as to thereby identify any compound included therein which specifically binds to the mammalian G protein-coupled receptor.

The invention also provides a process for determining whether a chemical compound is a ligand for a mammalian G protein-coupled receptor which comprises contacting cells transfected with and expressing DNA encoding a chimeric G protein and expressing DNA encoding a mammalian G protein-coupled receptor, with the compound under conditions permitting the activation of the mammalian G protein-coupled receptor, and detecting an increase in mammalian G protein-coupled receptor activity, so as to thereby determine whether the compound activates the mammalian G protein-coupled receptor and is a ligand for the mammalian G protein-coupled receptor.

The invention further provides a process for determining whether a chemical compound is a ligand

for a mammalian G protein-coupled receptor which comprises contacting a membrane preparation from cells transfected with and expressing DNA encoding a chimeric G protein and expressing DNA encoding a mammalian G protein-coupled receptor, with the compound under conditions permitting the activation of the mammalian G protein-coupled receptor, and detecting an increase in mammalian G protein-coupled receptor activity, so as to thereby determine whether the compound activates the mammalian G protein-coupled receptor and is a ligand for the mammalian G protein-coupled receptor.

The invention still further provides a process for determining whether a chemical compound is a ligand for a mammalian G protein-coupled receptor which comprises contacting cells producing a second messenger response, expressing the DNA encoding the mammalian G protein-coupled receptor, and expressing the DNA encoding a chimeric G protein, wherein such cells do not normally express the DNA encoding the chimeric G protein, with the chemical compound under conditions suitable for activation of the mammalian G protein-coupled receptor, and measuring the second messenger response in the presence and in the absence of the chemical compound, a change in the second messenger response in the presence of the chemical compound indicating that the compound activates the mammalian G protein-coupled receptor and is a ligand for the mammalian G protein-coupled receptor.

In addition, the invention provides a process of screening a plurality of chemical compounds not known to activate a mammalian G protein-coupled receptor to identify a ligand for the mammalian G protein-coupled receptor which comprises:

(a) contacting cells transfected with and expressing DNA encoding a chimeric G protein and expressing DNA encoding a mammalian G protein-coupled receptor with the plurality of compounds not known to activate the mammalian G protein-coupled receptor, under conditions permitting activation of the mammalian G protein-coupled receptor;

(b) determining whether the activity of the mammalian G protein-coupled receptor is increased in the presence of one or more of the compounds; and if so

(c) separately determining whether the activation of the mammalian G protein-coupled receptor is increased by any compound included in the plurality of compounds, so as to thereby identify each compound which activates the mammalian G protein-coupled receptor and is a ligand for the mammalian G protein-coupled receptor.

The invention also provides a process for determining whether a chemical compound is a ligand for a mammalian G protein-coupled receptor, which comprises separately contacting membrane preparations from cells transfected with and expressing DNA encoding a chimeric G protein and expressing DNA encoding a mammalian G protein-coupled receptor with both the compound and [<sup>35</sup>S]GTPγS, and with only [<sup>35</sup>S]GTPγS, under conditions permitting the activation of the mammalian G protein-coupled receptor, and detecting [<sup>35</sup>S]GTPγS binding to the membrane preparation and an increase in [<sup>35</sup>S]GTPγS binding in the presence of the

compound indicating that the chemical compound activates the mammalian G protein-coupled receptor and is a ligand for the mammalian G protein-coupled receptor.

5

In addition, the invention provides a process for determining whether a chemical compound is a ligand for the mammalian G protein-coupled receptor, which comprises contacting cells transfected with and  
10 expressing DNA encoding a chimeric G protein and expressing DNA encoding a mammalian G protein-coupled receptor with a compound, under conditions permitting the activation of the mammalian G protein-coupled receptor, and detecting changes in receptor active state conformation as manifested by changes in  
15 receptor/G protein heterotrimer association/dissociation in the presence of the compound indicating that the chemical compound activates the mammalian G protein-coupled receptor and is a ligand for the mammalian G protein-coupled  
20 receptor.

The invention further provides a process for identifying a ligand for a mammalian G protein-coupled receptor which comprises contacting cells  
25 transfected with and expressing DNA encoding a chimeric G protein and expressing DNA encoding a mammalian G protein-coupled receptor, wherein such cells do not normally express the DNA encoding the chimeric G protein, with the compound under  
30 conditions suitable for binding, and detecting specific binding of the chemical compound to the mammalian G protein-coupled receptor, indicating that the compound is a ligand for the mammalian G protein-coupled  
35 receptor.

The invention still further provides a process for identifying a chemical compound which specifically binds to a mammalian G protein-coupled receptor which comprises contacting a membrane preparation from  
5 cells transfected with and expressing DNA encoding a chimeric G protein and expressing DNA encoding a mammalian G protein-coupled receptor, wherein such cells do not normally express the DNA encoding the chimeric G protein, with the compound under  
10 conditions suitable for binding, and detecting specific binding of the chemical compound to the mammalian G protein-coupled receptor, indicating that the compound is a ligand for the mammalian G protein-coupled receptor.

The invention also provides a process of screening a plurality of independent clones not known to include a clone encoding a mammalian G protein-coupled receptor, to identify and isolate a clone encoding a  
20 mammalian G protein-coupled receptor, which comprises:

(a) contacting cells transfected with and expressing DNA encoding a chimeric G protein and expressing  
25 DNA encoding a plurality of independent clones with a ligand, under conditions permitting activation of a mammalian G protein-coupled receptor;

(b) determining whether the ligand activates the cells expressing the plurality of independent clones and the chimeric G protein; and if so

(c) isolating the single clone which expresses the  
35 mammalian G protein-coupled receptor activated by the ligand, so as to thereby identify any

clone included in the plurality of clones as encoding a mammalian G protein-coupled receptor.

5 The invention further provides a process of screening a plurality of independent clones not known to include a clone encoding a mammalian G protein-coupled receptor, to identify and isolate a clone encoding a mammalian G protein-coupled receptor,  
10 which comprises:

(a) contacting cells transfected with and expressing DNA encoding a chimeric G protein and expressing DNA encoding a plurality of independent clones with a ligand, under conditions permitting specific binding to a mammalian G protein-coupled receptor;  
15

(b) determining whether the ligand specifically binds to the cells expressing the plurality of independent clones and the chimeric G protein; and if so  
20

(c) isolating the single clone which expresses the mammalian G protein-coupled receptor which specifically binds to the ligand, so as to thereby identify any clone included in the plurality of clones as encoding a mammalian G protein-coupled receptor.  
25

## BRIEF DESCRIPTION OF THE FIGURES

### Figure 1

Phylogenetic tree of the  $G\alpha_q$  family of G proteins.  
 5 The tree was created using the "Growtree" algorithm  
 and specifying the "Cladogram" output (SeqLab version  
 10, Genetics Computer Group). Initially, a cladogram  
 was created from a multiple sequence alignment  
 ("Pileup" utility in SeqLab version 10, Genetics  
 10 Computer Group) of all publicly available G protein  
 sequences. The tree was then edited for clarity by  
 removing non- $G\alpha_q$  sequences. Double tilde indicates a  
 break in the branch to *Dictyostelium discoideum*  
 sequences imposed to permit page formatting. Branch  
 15 lengths are proportional to the number of accumulated  
 amino acid substitutions.

GBA2\_DICDI is *Dictyostelium discoideum*  $G\alpha_2$  (Genbank  
 Accession number P16051); GBA4\_DICDI is *Dictyostelium*  
 20 *discoideum*  $G\alpha_4$  (Genbank Accession number P34042);  
 GB16\_MOUSE is *Mus musculus* (mouse)  $G\alpha_{16}$  (Genbank  
 Accession number G193571); GB16\_HUMAN is *Homo sapiens*  
 (human)  $G\alpha_{16}$  (Genbank Accession number G182892);  
 GBQ\_PATYE is *Patinopecten yessoensis*  $G\alpha_q$  (GenBank  
 25 Accession number O15975); GBQ\_LYMST is *Lymnaea*  
*stagnalis*  $G\alpha_q$  (GenBank Accession number P38411);  
 GBQ\_HUMAN is *Homo sapiens* (human)  $G\alpha_q$  (Genbank  
 Accession number L76256); GBQ\_CANFA is *Canis*  
*familiarus*  $G\alpha_q$  (Genbank Accession number Q28294);  
 30 GBQ\_MOUSE is *Mus musculus* (mouse)  $G\alpha_q$  (Genbank  
 Accession number P21279); GBQ\_XENLA is *Xenopus laevis*  
 $G\alpha_q$  (Genbank Accession number P38410); GB11\_HUMAN is  
*Homo sapiens* (human)  $G\alpha_{11}$  (Genbank Accession number  
 29992); GB11\_BOVIN is *Bos taurus* (bovine)  $G\alpha_{11}$

(Genbank Accession number P38409); GB11\_MOUSE is *Mus musculus* (mouse)  $G\alpha_{11}$  (Genbank Accession number P21278); GB11\_MELGA is *Meleagris gallopavo*  $G\alpha_{11}$  (Genbank Accession number P45645); GB11\_XENLA is *Xenopus laevis*  $G\alpha_{11}$  (Genbank Accession number P43444); GBQ3\_DROME is *Drosophila melanogaster*  $G\alpha_{q3}$  (GenBank Accession number P54400); GBQ1\_DROME is *Drosophila melanogaster*  $G\alpha_{q1}$  (GenBank Accession number P23625); GBQ\_HOMAM is *Homarus americanus*  $G\alpha_q$  (GenBank Accession number P91950); GBQ\_CAEEL is *Caenorhabditis elegans*  $G\alpha_q$  (GenBank Accession number AF003739); GBQ\_LOLFO is *Loligo forbesi*  $G\alpha_q$  (GenBank Accession number P38412); GB14\_MOUSE is *Mus musculus* (mouse)  $G\alpha_{14}$  (Genbank Accession number P30677); GB14\_BOVIN is *Bos taurus* (bovine)  $G\alpha_{14}$  (Genbank Accession number P38408); and GBQ\_GEOCY is *Geodia cydonium*  $G\alpha_q$  (GenBank Accession number  $\gamma$ 14248).

### **Figure 2A-2B**

Amino acid sequences of  $G\alpha_{q/x}$  chimeras. (*C. elegans*  $G\alpha_{q/z5}$  (SEQ ID NO: 1); *C. elegans*  $G\alpha_{q/z9}$  (SEQ ID NO: 2); *C. elegans*  $G\alpha_{q/s9}$  (SEQ ID NO: 3); *C. elegans*  $G\alpha_{q/s21}$  (SEQ ID NO: 4); *C. elegans*  $G\alpha_{q/i3(5)}$  (SEQ ID NO: 5); and *D. melanogaster*  $G\alpha_{q/zs}$  (SEQ ID NO: 41)). Bold regions at the C-terminus denote where amino acid substitutions are made between *C. elegans*  $G\alpha_q$  and mammalian  $G\alpha_z$ ,  $G\alpha_s$ , or  $G\alpha_{i3}$ . The remainder of the protein (non-bold amino acids) in each case is *C. elegans* or *D. melanogaster*  $G\alpha_q$ .

### **Figure 3**

Examples of receptor-evoked responses in oocytes expressing c $G\alpha_{q/z5}$  or h $G\alpha_{q/z5}$  chimeric G proteins.

**Figure 4**

Examples of receptor-evoked responses in mammalian cells expressing cG $\alpha_{q/z5}$  or hG $\alpha_{q/z5}$  chimeric G proteins plus the human D1 receptor. Transiently transfected COS-7 cells were seeded into a 96-well microtiter plate and monitored for calcium mobilization in the FLIPR<sup>TM</sup> using the calcium-sensitive dye Fluo-3. A) Representative time course of fluorescence in cells stimulated at time = 10 seconds with 100  $\mu$ M dopamine. Each curve is derived from a representative well. B) Maximal change in relative fluorescent units was calculated for dopamine concentrations ranging from 0.3 nM to 100  $\mu$ M. Triplicate determinations, plotted as mean  $\pm$  standard error of the mean, were used to construct concentration-response curves. In the example shown here, a measurable response to dopamine was obtained only in the presence of cG $\alpha_{q/z5}$ , with a maximal signal of 14,723 fluorescence units and pEC<sub>50</sub> of 6.32. Average maximal responses from multiple experiments (n  $\geq$  2) are listed in Table 5.

**Figures 5A-5C**

Multiple sequence alignment of G $\alpha_q$  proteins from invertebrate and vertebrate organisms. Sequences were aligned using "Pileup" (SeqLab version 10, Genetics Computer Group). The degree of amino acid identity is indicated by the level of shading (black, 100% identity, white < 60%).

GBQ\_HUMAN is *Homo sapiens* (human) G $\alpha_q$  (Genbank Accession number L76256; SEQ ID NO: 6); GBQ\_CANFA is *Canis familiaris* G $\alpha_q$  (Genbank Accession number Q28294; SEQ ID NO: 7); GBQ\_MOUSE is *Mus musculus* (mouse) G $\alpha_q$  (Genbank Accession number P21279; SEQ ID NO: 8);

GBQ\_XENLA is *Xenopus laevis*  $G\alpha_q$  (Genbank Accession  
 number P38410; SEQ ID NO: 9); GBQ\_PATYE is  
*Patinopecten yessoensis*  $G\alpha_q$  (GenBank Accession number  
 O15975; SEQ ID NO: 10); GBQ\_LYMST is *Lymnaea*  
 5 *stagnalis*  $G\alpha_q$  (GenBank Accession number P38411; SEQ ID  
 NO: 11); GBQ1\_DROME is *Drosophila melanogaster*  $G\alpha_{q1}$   
 (GenBank Accession number P23625; SEQ ID NO: 12);  
 GBQ3\_DROME is *Drosophila melanogaster*  $G\alpha_{q3}$  (GenBank  
 Accession number P54400; SEQ ID NO: 13); GBQ\_HOMAM is  
 10 *Homarus americanus*  $G\alpha_q$  (GenBank Accession number  
 P91950; SEQ ID NO: 14); GBQ\_LIMPO is *Limulus*  
*polyphemus*  $G\alpha_q$  (Genbank Accession number g1857923; SEQ  
 ID NO: 15); GBQ\_LOLFO is *Loligo forbesi*  $G\alpha_q$  (GenBank  
 Accession number P38412; SEQ ID NO: 16); GBQ\_CAEEL is  
 15 *Caenorhabditis elegans*  $G\alpha_q$  (GenBank Accession number  
 AF003739; SEQ ID NO: 17); GBQ\_GEOCY is *Geodia*  
*cydonium*  $G\alpha_q$  (GenBank Accession number 14248; SEQ ID  
 NO: 18).

**DETAILED DESCRIPTION OF THE INVENTION**

The following definitions are presented as an aid in understanding this invention.

5

For the purposes of this invention, "ligand" is a molecule capable of binding to and modulating a receptor. The ligand may be chemically synthesized or may occur in nature.

10

For the purposes of this invention, "agonist" is a ligand capable of stimulating the biological activity of a receptor.

15

For the purposes of this invention, "antagonist" is a ligand capable of inhibiting the biological activity of a receptor.

20

For the purposes of this invention, "invertebrate" species are defined as those members of the Animal Kingdom that do not possess a vertebral column or backbone (Barnes, 1974).

25

For the purposes of this invention, in one embodiment, an invertebrate Gαq G protein has amino acids QK at positions 12 and 13 from the N-terminus and does not contain the sequence MTLESI (SEQ ID NO: 36) at the N-terminus.

30

For the purposes of this invention, "vertebrate" species are those members of the Animal Kingdom that do possess a vertebral column or backbone (Barnes, 1974). A common characteristic of vertebrate Gαq G proteins is an N-terminal extension composed of the amino acids MTLESI (SEQ ID NO: 36).

35

For the purposes of this invention, "G $\alpha$ q second messenger response" is one of a number of responses which are typically produced by activation of G protein heterotrimers containing G $\alpha$ q.

For the purposes of this invention, "G $\alpha$ s second messenger response" is one of a number of responses which are typically produced by activation of G protein heterotrimers containing G $\alpha$ s.

For the purposes of this invention, "receptor/G protein heterotrimer association/ dissociation" means a change in the intermolecular relationship between either  $\alpha$ - $\beta$ - $\gamma$  subunits themselves or one or more of these subunits with the receptor.

Having due regard to the preceding definitions, the present invention provides an isolated nucleic acid encoding a chimeric G protein, wherein the chimeric G protein comprises an invertebrate G $\alpha$ q G protein from which at least five, but not more than twenty-one, contiguous amino acids beginning with the C-terminal amino acid have been deleted and replaced by a number of contiguous amino acids present in a vertebrate G protein beginning with the C-terminal amino acid of such vertebrate G protein, wherein such number equals the number of amino acids deleted or varies therefrom by no more than five amino acids, provided that at least five of the C-terminal amino acids of the chimeric G protein are present at the C-terminus of such vertebrate G protein.

In one embodiment, the nucleic acid encodes a chimeric G protein, wherein the chimeric G protein

comprises an invertebrate Gαq G protein from which at least five, but not more than twenty-one, contiguous amino acids beginning with the C-terminal amino acid have been deleted and replaced by a number of contiguous amino acids present in a vertebrate G protein beginning with the C-terminal amino acid of such vertebrate G protein, wherein such number equals the number of amino acids deleted or varies therefrom by no more than two amino acids, provided that at least five of the C-terminal amino acids of the chimeric G protein are present at the C-terminus of such vertebrate G protein.

In another embodiment, the nucleic acid encodes a chimeric G protein, wherein the chimeric G protein comprises an invertebrate Gαq G protein from which at least five, but not more than twenty-one, contiguous amino acids beginning with the C-terminal amino acid have been deleted and replaced by a number of contiguous amino acids present in a vertebrate G protein beginning with the C-terminal amino acid of such vertebrate G protein, wherein such number equals the number of amino acids deleted.

In one embodiment, the nucleic acid is DNA. In one embodiment, the DNA is cDNA. In another embodiment, the DNA is genomic DNA. In another embodiment, the nucleic acid is RNA.

In one embodiment, the aforementioned vertebrate G protein is a mammalian G protein. In another embodiment, the aforementioned contiguous amino acids which have been deleted are contained in FVFAAVKDTILQHNLLKEYNLV\* (SEQ ID NO: 37), wherein V\* is the C-terminal amino acid.

In another embodiment, the vertebrate G protein is a vertebrate G $\alpha$ z G protein. In another embodiment, the number of contiguous amino acids which have replaced the deleted amino acids are contained in  
 5 FVFDAVTDVIIQNNLKYIGLC\* (SEQ ID NO: 38), wherein C\* is the C-terminal amino acid. In another embodiment, the aforementioned invertebrate G $\alpha$ q G protein has five contiguous amino acids beginning with the C-terminal amino acid which have been deleted and  
 10 replaced by five contiguous amino acids beginning with the C-terminal amino acid of the vertebrate G $\alpha$ z protein.

In another embodiment, the vertebrate G protein is a vertebrate G $\alpha$ s G protein. In another embodiment, the number of contiguous amino acids which have replaced the deleted amino acids are contained in  
 15 RVFNDCRDIQRMHLRQYELL\* (SEQ ID NO: 39), wherein L\* is the C-terminal amino acid. In another embodiment, the invertebrate G $\alpha$ q G protein has nine contiguous amino acids beginning with the C-terminal amino acid which have been deleted and replaced by nine  
 20 contiguous amino acids beginning with the C-terminal amino acid of the vertebrate G $\alpha$ s protein.

25 In another embodiment, the vertebrate G protein is a vertebrate G $\alpha$ i3 G protein. In another embodiment, the number of contiguous amino acids which have replaced the deleted amino acids are contained in  
 30 FVFDAVTDVIIKNNLKECGLY\* (SEQ ID NO: 40), wherein Y\* is the C-terminal amino acid. In another embodiment, the invertebrate G $\alpha$ q G protein has five contiguous amino acids beginning with the C-terminal amino acid which have been deleted and replaced by five

contiguous amino acids beginning with the C-terminal amino acid of the vertebrate  $G\alpha i3$  protein.

5 In other embodiments, the vertebrate G protein is a vertebrate  $G\alpha i1$  G protein, a vertebrate  $G\alpha i2$  G protein, a vertebrate  $G\alpha oA$  G protein, or a vertebrate  $G\alpha oB$  G protein.

10 In another embodiment, the invertebrate  $G\alpha q$  G protein is a *Caenorhabditis elegans*  $G\alpha q$  G protein. In still other embodiments, the invertebrate  $G\alpha q$  G protein is a *Drosophila melanogaster*  $G\alpha q$  G protein, a *Limulus polyphemus*  $G\alpha q$  G protein, a *Patinopecten yessoensis*  $G\alpha q$  G protein, a *Loligo forbesi*  $G\alpha q$  G protein, a  
15 *Homarus americanus*  $G\alpha q$  G protein, a *Lymnaea stagnalis*  $G\alpha q$  G protein, a *Geodia cydonium*  $G\alpha q$  G protein, or a *Dictyostelium discoideum*  $G\alpha_4$  G protein.

20 In other embodiments, the chimeric G protein has an amino acid sequence substantially the same as the amino acid sequence shown in (a) Figure 2, *C. elegans*  $G\alpha_{q/z5}$  (SEQ ID NO: 1); (b) Figure 2, *C. elegans*  $G\alpha_{q/z9}$  (SEQ ID NO: 2); (c) Figure 2, *C. elegans*  $G\alpha_{q/s9}$  (SEQ ID NO: 3); (d) Figure 2, *C. elegans*  $G\alpha_{q/s21}$  (SEQ ID NO: 4); (e) Figure 2, *C. elegans*  $G\alpha_{q/i3(5)}$  (SEQ ID NO: 5);  
25 or (f) Figure 2, *D. melanogaster*  $G\alpha_{q/zs}$  (SEQ ID NO: 41).

30 The invention provides a vector comprising any of the aforementioned nucleic acids. In different embodiments, the vector is adapted for expression in a cell which comprises the regulatory elements necessary for expression of the nucleic acid in the cell operatively linked to the nucleic acid encoding

the chimeric G protein so as to permit expression thereof, wherein the cell is a bacterial, amphibian, yeast, insect, or mammalian cell. In different embodiments, the vector is a plasmid, a baculovirus, or a retrovirus.

The invention provides a cell comprising any of the aforementioned vectors, wherein the cell comprises DNA encoding a mammalian G protein-coupled receptor. In one embodiment of the cell, the DNA encoding the mammalian G protein-coupled receptor is endogenous to the cell. In another embodiment, the DNA encoding the mammalian G protein-coupled receptor is transfected into the cell. In one embodiment, the cell is a non-mammalian cell. In different embodiments, the non-mammalian cell is a *Xenopus* oocyte cell or a *Xenopus* melanophore cell. In another embodiment, the cell is a mammalian cell. In different embodiments, the mammalian cell is a COS-7 cell, a 293 human embryonic kidney cell, a NIH-3T3 cell, a LM(tk-) cell, a mouse Y1 cell, or a CHO cell. In one embodiment, the cell is an insect cell. In different embodiments, the insect cell is an Sf9 cell, an Sf21 cell or a *Trichoplusia ni* 5B-4 cell. The invention provides a membrane preparation isolated from any of the aforementioned cells.

The invention also provides a process for determining whether a chemical compound is a mammalian G protein-coupled receptor agonist which comprises contacting cells transfected with and expressing DNA encoding a chimeric G protein and expressing DNA encoding a mammalian G protein-coupled receptor, with the compound under conditions permitting the activation of the mammalian G protein-coupled receptor, and detecting an increase in mammalian G protein-coupled

receptor activity, so as to thereby determine whether the compound is a mammalian G protein-coupled receptor agonist.

5 The invention further provides a process for determining whether a chemical compound is a mammalian G protein-coupled receptor agonist which comprises contacting a membrane preparation from cells transfected with and expressing DNA encoding a  
10 chimeric G protein and expressing DNA encoding a mammalian G protein-coupled receptor, with the compound under conditions permitting the activation of the mammalian G protein-coupled receptor, and detecting an increase in mammalian G protein-coupled  
15 receptor activity, so as to thereby determine whether the compound is a mammalian G protein-coupled receptor agonist.

The invention also provides a process for determining  
20 whether a chemical compound is a mammalian G protein-coupled receptor antagonist which comprises contacting cells transfected with and expressing DNA encoding a chimeric G protein and expressing DNA encoding a mammalian G protein-coupled receptor, with  
25 the compound in the presence of a known mammalian G protein-coupled receptor agonist, under conditions permitting the activation of the mammalian G protein-coupled receptor, and detecting a decrease in mammalian G protein-coupled receptor activity, so as  
30 to thereby determine whether the compound is a mammalian G protein-coupled receptor antagonist.

The invention further provides a process for determining whether a chemical compound is a  
35 mammalian G protein-coupled receptor antagonist which comprises contacting a membrane preparation from

cells transfected with and expressing DNA encoding a chimeric G protein and expressing DNA encoding a mammalian G protein-coupled receptor, with the compound in the presence of a known mammalian G protein-coupled receptor agonist, under conditions permitting the activation of the mammalian G protein-coupled receptor, and detecting a decrease in mammalian G protein-coupled receptor activity, so as to thereby determine whether the compound is a mammalian G protein-coupled receptor antagonist.

In one embodiment of any of the aforementioned processes, the DNA encoding the mammalian G protein-coupled receptor is endogenous to the cell. In another embodiment, the DNA encoding the mammalian G protein-coupled receptor is transfected into the cell. In different embodiments, the mammalian G protein-coupled receptor is a human Y5 receptor, a human GALR2 receptor, a human kappa opioid receptor, a human NPFF1 receptor, a human NPFF2 receptor, a human  $\alpha$ 2A adrenergic receptor, a human dopamine D2 receptor, a human GALR1 receptor, a human Y2 receptor, a human Y1 receptor, a human Y4 receptor, a human  $\alpha$ 1A adrenergic receptor, a human dopamine D1 receptor, or a rat NTR1 receptor.

The invention also provides a process for determining whether a chemical compound specifically binds to and activates a mammalian G protein-coupled receptor, which comprises contacting cells producing a second messenger response, expressing the DNA encoding the mammalian G protein-coupled receptor, and expressing the DNA encoding a chimeric G protein, wherein such cells do not normally express the DNA encoding the chimeric G protein, with the chemical compound under conditions suitable for activation of the mammalian G

protein-coupled receptor, and measuring the second messenger response in the presence and in the absence of the chemical compound, a change in the second messenger response in the presence of the chemical compound indicating that the compound activates the mammalian G protein-coupled receptor. In one embodiment of the process, the DNA encoding the mammalian G protein-coupled receptor is endogenous to the cell. In another embodiment, DNA encoding the mammalian G protein-coupled receptor is transfected into the cell.

In one embodiment of the aforementioned process, the second messenger response is the detection of a reporter protein under the transcriptional control of a promoter element. In another embodiment, the second messenger response is measured by a change in cell proliferation. In another embodiment, the second messenger response is a  $G\alpha q$  second messenger response. In one embodiment, the  $G\alpha q$  second messenger response comprises release of inositol phosphate and the change in second messenger is an increase in the level of inositol phosphate. In another embodiment, the  $G\alpha q$  second messenger response comprises release of arachidonic acid and the change in second messenger is an increase in the level of arachidonic acid. In another embodiment, the  $G\alpha q$  second messenger response comprises activation of MAP kinase and the change in second messenger response is an increase in MAP kinase activation. In another embodiment, the  $G\alpha q$  second messenger response comprises intracellular calcium levels and the change in second messenger is an increase in the measure of intracellular calcium. In one embodiment, the measure of intracellular calcium levels is made by

chloride current readings. In other embodiments, the measure of intracellular calcium is made by fluorescence readings, luminescence readings, electrophysiological readings, or through the detection of a reporter protein under the transcriptional control of a calcium-responsive promoter element.

In addition, the invention provides a process for determining whether a chemical compound specifically binds to and inhibits activation of a mammalian G protein-coupled receptor, which comprises separately contacting cells producing a second messenger response, expressing the DNA encoding the mammalian G protein-coupled receptor, and expressing the DNA encoding a chimeric G protein, wherein such cells do not normally express the DNA encoding the chimeric G protein, with both the chemical compound and a second chemical compound known to activate the mammalian G protein-coupled receptor, and with only the second chemical compound, under conditions suitable for activation of the mammalian G protein-coupled receptor, and measuring the second messenger response in the presence of only the second chemical compound and in the presence of both the second chemical compound and the chemical compound, a smaller change in the second messenger response in the presence of both the chemical compound and the second chemical compound than in the presence of only the second chemical compound indicating that the chemical compound inhibits activation of the mammalian G protein-coupled receptor. In one embodiment of the process, the DNA encoding the mammalian G protein-coupled receptor is endogenous to the cell. In another embodiment, DNA encoding the mammalian G

protein-coupled receptor is transfected into the cell.

In one embodiment of the aforementioned process, the  
5 second messenger response is the detection of a  
reporter protein under the transcriptional control of  
a promoter element. In another embodiment, the  
second messenger response is measured by a change in  
cell proliferation. In another embodiment, the  
10 second messenger response is a Gαq second messenger  
response. In one embodiment, the Gαq second  
messenger response comprises release of inositol  
phosphate and the change in second messenger response  
is a smaller increase in the level of inositol  
15 phosphate in the presence of both the chemical  
compound and the second chemical compound than in the  
presence of only the second chemical compound. In  
another embodiment, the Gαq second messenger response  
comprises activation of MAP kinase and the change in  
20 second messenger response is a smaller increase in  
the level of MAP kinase activation in the presence of  
both the chemical compound and the second chemical  
compound than in the presence of only the second  
chemical compound. In another embodiment, the Gαq  
25 second messenger response comprises release of  
arachidonic acid and the change in second messenger  
response is an increase in the level of arachidonic  
acid levels in the presence of both the chemical  
compound and the second chemical compound than in the  
30 presence of only the second chemical compound. In  
another embodiment, the Gαq second messenger response  
comprises change in intracellular calcium levels and  
the change in second messenger response is a smaller  
increase in the measure of intracellular calcium in  
35 the presence of both the chemical compound and the

second chemical compound than in the presence of only the second chemical compound. In one embodiment, the measure of intracellular calcium levels is made by chloride current readings. In other embodiments, the measure of intracellular calcium is made by fluorescence readings, luminescence readings, electrophysiological readings, or through the detection of a reporter protein under the transcriptional control of a calcium-responsive promoter element.

The invention also provides a process of screening a plurality of chemical compounds not known to activate a mammalian G protein-coupled receptor to identify a compound which activates the mammalian G protein-coupled receptor which comprises:

- (a) contacting cells transfected with and expressing DNA encoding a chimeric G protein and expressing DNA encoding a mammalian G protein-coupled receptor with the plurality of compounds not known to activate the mammalian G protein-coupled receptor, under conditions permitting activation of the mammalian G protein-coupled receptor;
- (b) determining whether the activity of the mammalian G protein-coupled receptor is increased in the presence of one or more of the compounds; and if so
- (c) separately determining whether the activation of the mammalian G protein-coupled receptor is increased by any compound included in the plurality of compounds, so as to thereby

identify each compound which activates the mammalian G protein-coupled receptor.

The invention further provides a process of screening a plurality of chemical compounds not known to inhibit the activation of a mammalian G protein-coupled receptor to identify a compound which inhibits the activation of the mammalian G protein-coupled receptor, which comprises:

(a) contacting cells transfected with and expressing DNA encoding a chimeric G protein and expressing DNA encoding a mammalian G protein-coupled receptor with the plurality of compounds in the presence of a known mammalian G protein-coupled receptor agonist, under conditions permitting activation of the mammalian G protein-coupled receptor;

(b) determining whether the extent or amount of activation of the mammalian G protein-coupled receptor is reduced in the presence of one or more of the compounds, relative to the extent or amount of activation of the mammalian G protein-coupled receptor in the absence of such one or more compounds; and if so

(c) separately determining whether each such compound inhibits activation of the mammalian G protein-coupled receptor for each compound included in the plurality of compounds, so as to thereby identify any compound included in such plurality of compounds which inhibits the activation of the mammalian G protein-coupled receptor.

In one embodiment of the aforementioned processes, the DNA encoding the mammalian G protein-coupled receptor is endogenous to the cell. In another embodiment, the DNA encoding the mammalian G protein-coupled receptor is transfected into the cell.

The invention also provides a process for determining whether a chemical compound is a mammalian G protein-coupled receptor agonist, which comprises separately contacting membrane preparations from cells transfected with and expressing DNA encoding a chimeric G protein and expressing DNA encoding a mammalian G protein-coupled receptor with both the compound and [<sup>35</sup>S]GTPγS, and with only [<sup>35</sup>S]GTPγS, under conditions permitting the activation of the mammalian G protein-coupled receptor, and detecting [<sup>35</sup>S]GTPγS binding to the membrane preparation and an increase in [<sup>35</sup>S]GTPγS binding in the presence of the compound indicating that the chemical compound activates the mammalian G protein-coupled receptor.

The invention further provides a process for determining whether a chemical compound is a mammalian G protein-coupled receptor antagonist which comprises separately contacting membrane preparations from cells transfected with and expressing DNA encoding a chimeric G protein and expressing DNA encoding a mammalian G protein-coupled receptor with the chemical compound, [<sup>35</sup>S]GTPγS, and a second chemical compound known to activate the mammalian G protein-coupled receptor, with [<sup>35</sup>S]GTPγS and only the second compound, and with [<sup>35</sup>S]GTPγS alone, under conditions permitting the activation of the mammalian G protein-coupled receptor, detecting [<sup>35</sup>S]GTPγS binding to each membrane preparation, comparing the

increase in [<sup>35</sup>S]GTPγS binding in the presence of the compound and the second compound relative to the binding of [<sup>35</sup>S]GTPγS alone to the increase in [<sup>35</sup>S]GTPγS binding in the presence of the second chemical compound relative to the binding of [<sup>35</sup>S]GTPγS alone, and detecting a smaller increase in [<sup>35</sup>S]GTPγS binding in the presence of the compound and the second compound indicating that the compound is a mammalian G protein-coupled receptor antagonist.

In one embodiment of the aforementioned processes, the DNA encoding the mammalian G protein-coupled receptor is endogenous to the cell. In another embodiment, the DNA encoding the mammalian G protein-coupled receptor is transfected into the cell. In one embodiment, the mammalian G protein-coupled receptor produces a Gαs second messenger response in the absence of the chimeric G protein.

This invention also provides a process for determining whether a chemical compound is a mammalian G protein-coupled receptor agonist, which comprises contacting cells transfected with and expressing DNA encoding a chimeric G protein and expressing DNA encoding a mammalian G protein-coupled receptor with a compound, under conditions permitting the activation of the mammalian G protein-coupled receptor, and detecting changes in receptor active state conformation as manifested by changes in receptor/G protein heterotrimer association/dissociation in the presence of the compound indicating that the chemical compound activates the mammalian G protein-coupled receptor.

This invention further provides a process for determining whether a chemical compound is a mammalian G protein-coupled receptor antagonist which comprises separately contacting cells transfected with and expressing DNA encoding a chimeric G protein and expressing DNA encoding a mammalian G protein-coupled receptor with the chemical compound in the presence of a known mammalian G protein-coupled receptor agonist, under conditions permitting the activation of the mammalian G protein-coupled receptor, and detecting changes in receptor active state conformation as manifested by changes in receptor/G protein heterotrimer association/dissociation in the presence of the compound indicating that the compound is a mammalian G protein-coupled receptor antagonist.

In one embodiment of the aforementioned processes, the DNA encoding the mammalian G protein-coupled receptor is endogenous to the cell. In another embodiment, the DNA encoding the mammalian G protein-coupled receptor is transfected into the cell.

In one embodiment of any of the aforementioned processes, the chimeric G protein comprises an invertebrate  $G\alpha_q$  G protein from which at least five, but not more than twenty-one, contiguous amino acids beginning with the C-terminal amino acid have been deleted and replaced by a number of contiguous amino acids present in a vertebrate G protein beginning with the C-terminal amino acid of such vertebrate G protein, wherein such number equals the number of amino acids deleted. In another embodiment, the chimeric G protein comprises an invertebrate  $G\alpha_q$  G protein from which at least five, but not more than twenty-one, contiguous amino acids beginning with the

C-terminal amino acid have been deleted and replaced by a number of contiguous amino acids present in a vertebrate Gαz protein beginning with the C-terminal amino acid of such vertebrate Gαz protein, wherein such number equals the number of amino acids deleted.

5 In another embodiment, the chimeric G protein comprises an invertebrate Gαq G protein from which at least five, but not more than twenty-one, contiguous amino acids beginning with the C-terminal amino acid

10 have been deleted and replaced by a number of contiguous amino acids present in a vertebrate Gαs protein beginning with the C-terminal amino acid of such vertebrate Gαs protein, wherein such number equals the number of amino acids deleted. In another

15 embodiment, the chimeric G protein comprises an invertebrate Gαq G protein from which at least five, but not more than twenty-one, contiguous amino acids beginning with the C-terminal amino acid have been deleted and replaced by a number of contiguous amino

20 acids present in a vertebrate Gαi3 protein beginning with the C-terminal amino acid of such vertebrate Gαi3 protein, wherein such number equals the number of amino acids deleted.

25 In another embodiment, the chimeric G protein comprises a *Caenorhabditis elegans* Gαq G protein from which at least five, but not more than twenty-one, contiguous amino acids beginning with the C-terminal amino acid have been deleted and replaced by a number

30 of contiguous amino acids present in a vertebrate G protein beginning with the C-terminal amino acid of such vertebrate G protein, wherein such number equals the number of amino acids deleted. In other embodiments, the chimeric G protein comprises a

35 *Drosophila melanogaster* Gαq G protein, a *Limulus*

*polyphemus*  $G\alpha_q$  G protein, a *Patinopecten yessoensis*  $G\alpha_q$  G protein, a *Loligo forbesi*  $G\alpha_q$  G protein, a *Homarus americanus*  $G\alpha_q$  G protein, a *Lymnaea stagnalis*  $G\alpha_q$  G protein, a *Geodia cydonium*  $G\alpha_q$  G protein, or a  
 5 *Dictyostelium discoideum*  $G\alpha_4$  G protein, from which at least five, but not more than twenty-one, contiguous amino acids beginning with the C-terminal amino acid have been deleted and replaced by a number of contiguous amino acids present in a vertebrate G  
 10 protein beginning with the C-terminal amino acid of a vertebrate G protein, wherein such number equals the number of amino acids deleted. In other embodiments, the chimeric G protein has an amino acid sequence substantially the same as the amino acid sequence  
 15 shown in (a) Figure 2, *C. elegans*  $G\alpha_{q/z5}$  (SEQ ID NO: 1); (b) Figure 2, *C. elegans*  $G\alpha_{q/z9}$  (SEQ ID NO: 2); (c) Figure 2, *C. elegans*  $G\alpha_{q/s9}$  (SEQ ID NO: 3); (d) Figure 2, *C. elegans*  $G\alpha_{q/s21}$  (SEQ ID NO: 4); (e) Figure 2, *C. elegans*  $G\alpha_{q/i3(5)}$  (SEQ ID NO: 5); or (f) Figure  
 20 2, *D. melanogaster*  $G\alpha_{q/zs}$  (SEQ ID NO: 41).

In one embodiment of any of the aforementioned processes, the cell is an insect cell. In another  
 25 embodiment, the cell is a mammalian cell. In one embodiment, the mammalian cell is nonneuronal in origin. In further embodiments, the nonneuronal cell is a COS-7 cell, 293 human embryonic kidney cell, a CHO cell, a NIH-3T3 cell, a mouse Y1 cell, or a  
 30 LM(tk-) cell.

The invention also provides a process for identifying a chemical compound which specifically binds to a  
 35 mammalian G protein-coupled receptor which comprises contacting cells transfected with and expressing DNA

encoding a chimeric G protein and expressing DNA  
encoding a mammalian G protein-coupled receptor,  
wherein such cells do not normally express the DNA  
encoding the chimeric G protein, with the compound  
5 under conditions suitable for binding, and detecting  
specific binding of the chemical compound to the  
mammalian G protein-coupled receptor.

The invention further provides a process for  
10 identifying a chemical compound which specifically  
binds to a mammalian G protein-coupled receptor which  
comprises contacting a membrane preparation from  
cells transfected with and expressing DNA encoding a  
chimeric G protein and expressing DNA encoding a  
15 mammalian G protein-coupled receptor, wherein such  
cells do not normally express the DNA encoding the  
chimeric G protein, with the compound under  
conditions suitable for binding, and detecting  
specific binding of the chemical compound to the  
20 mammalian G protein-coupled receptor.

In addition, the invention provides a process  
involving competitive binding for identifying a  
chemical compound which specifically binds to a  
25 mammalian G protein-coupled receptor which comprises  
separately contacting cells transfected with and  
expressing DNA encoding a chimeric G protein and  
expressing DNA encoding a mammalian G protein-coupled  
receptor, wherein such cells do not normally express  
30 the DNA encoding the chimeric G protein, with both  
the chemical compound and a second chemical compound  
known to bind to the mammalian G protein-coupled  
receptor, and with only the second chemical compound,  
under conditions suitable for binding of both  
35 compounds, and detecting specific binding of the  
chemical compound to the mammalian G protein-coupled

receptor, a decrease in the binding of the second chemical compound to the mammalian G protein-coupled receptor in the presence of the chemical compound indicating that the chemical compound binds to the mammalian G protein-coupled receptor.

5 The invention further provides a process involving competitive binding for identifying a chemical compound which specifically binds to a mammalian G protein-coupled receptor which comprises separately  
10 contacting a membrane preparation from cells transfected with and expressing DNA encoding a chimeric G protein and expressing DNA encoding a mammalian G protein-coupled receptor, wherein such  
15 cells do not normally express the DNA encoding the chimeric G protein, with both the chemical compound and a second chemical compound known to bind to the receptor, and with only the second chemical compound, under conditions suitable for binding of both  
20 compounds, and detecting specific binding of the chemical compound to the mammalian G protein-coupled receptor, a decrease in the binding of the second chemical compound to the mammalian G protein-coupled receptor in the presence of the chemical compound  
25 indicating that the chemical compound binds to the mammalian G protein-coupled receptor.

The invention also provides a process of screening a plurality of chemical compounds not known to bind to  
30 a mammalian G protein-coupled receptor to identify a compound which specifically binds to the mammalian G protein-coupled receptor, which comprises

(a) contacting cells transfected with and expressing  
35 DNA encoding a chimeric G protein and expressing DNA encoding a mammalian G protein-coupled

receptor with a compound known to bind specifically to the mammalian G protein-coupled receptor;

- 5 (b) contacting the cells of step (a) with the plurality of compounds not known to bind specifically to the mammalian G protein-coupled receptor, under conditions permitting binding of compounds known to bind to the mammalian G  
10 protein-coupled receptor;
- (c) determining whether the binding of the compound known to bind to the mammalian G protein-coupled receptor is reduced in the presence of the  
15 plurality of compounds, relative to the binding of the compound in the absence of the plurality of compounds; and if so
- (d) separately determining the binding to the  
20 mammalian G protein-coupled receptor of each compound included in the plurality of compounds, so as to thereby identify any compound included therein which specifically binds to the mammalian G protein-coupled receptor.

25

The invention further provides a process of screening a plurality of chemical compounds not known to bind to a mammalian G protein-coupled receptor to identify a compound which specifically binds to the mammalian  
30 G protein-coupled receptor, which comprises

- (a) contacting a membrane preparation from cells transfected with and expressing DNA encoding a chimeric G protein and expressing DNA encoding a  
35 mammalian G protein-coupled receptor with the plurality of compounds not known to bind

specifically to the mammalian G protein-coupled receptor under conditions permitting binding of compounds known to bind to the mammalian G protein-coupled receptor;

5

(b) determining whether the binding of a compound known to bind to the mammalian G protein-coupled receptor is reduced in the presence of the plurality of compounds, relative to the binding of the compound in the absence of the plurality of compounds; and if so

10

(c) separately determining the binding to the mammalian G protein-coupled receptor of each compound included in the plurality of compounds, so as to thereby identify any compound included therein which specifically binds to the mammalian G protein-coupled receptor.

15

In one embodiment of any of the aforementioned processes, the DNA encoding the mammalian G protein-coupled receptor is endogenous to the cell. In another embodiment, the DNA encoding the mammalian G protein-coupled receptor is transfected into the cell.

20

25

In one embodiment of any of the aforementioned processes, the chimeric G protein comprises an invertebrate  $G\alpha_q$  G protein from which at least five, but not more than twenty-one, contiguous amino acids beginning with the C-terminal amino acid have been deleted and replaced by a number of contiguous amino acids present in a vertebrate G protein beginning with the C-terminal amino acid of such vertebrate G protein, wherein such number equals the number of amino acids deleted. In another embodiment, the

30

35

chimeric G protein comprises an invertebrate G $\alpha$ q G protein from which at least five, but not more than twenty-one, contiguous amino acids beginning with the C-terminal amino acid have been deleted and replaced by a number of contiguous amino acids present in a vertebrate G $\alpha$ z protein beginning with the C-terminal amino acid of such vertebrate G $\alpha$ z protein, wherein such number equals the number of amino acids deleted. In another embodiment, the chimeric G protein comprises an invertebrate G $\alpha$ q G protein from which at least five, but not more than twenty-one, contiguous amino acids beginning with the C-terminal amino acid have been deleted and replaced by a number of contiguous amino acids present in a vertebrate G $\alpha$ s protein beginning with the C-terminal amino acid of such vertebrate G $\alpha$ s protein, wherein such number equals the number of amino acids deleted. In another embodiment, the chimeric G protein comprises an invertebrate G $\alpha$ q G protein from which at least five, but not more than twenty-one, contiguous amino acids beginning with the C-terminal amino acid have been deleted and replaced by a number of contiguous amino acids present in a vertebrate G $\alpha$ i3 protein beginning with the C-terminal amino acid of such vertebrate G $\alpha$ i3 protein, wherein such number equals the number of amino acids deleted.

In another embodiment, the chimeric G protein comprises an *Caenorhabditis elegans* G $\alpha$ q G protein from which at least five, but not more than twenty-one, contiguous amino acids beginning with the C-terminal amino acid have been deleted and replaced by a number of contiguous amino acids present in a vertebrate G protein beginning with the C-terminal amino acid of such vertebrate G protein, wherein such

number equals the number of amino acids deleted. In other embodiments, the chimeric G protein comprises a *Drosophila melanogaster*  $G\alpha_q$  G protein, a *Limulus polyphemus*  $G\alpha_q$  G protein, a *Patinopecten yessoensis*  $G\alpha_q$  G protein, a *Loligo forbesi*  $G\alpha_q$  G protein, a *Homarus americanus*  $G\alpha_q$  G protein, a *Lymnaea stagnalis*  $G\alpha_q$  G protein, a *Geodia cydonium*  $G\alpha_q$  G protein, or a *Dictyostelium discoideum*  $G\alpha_4$  G protein, from which at least five, but not more than twenty-one, contiguous amino acids beginning with the C-terminal amino acid have been deleted and replaced by a number of contiguous amino acids present in a vertebrate G protein beginning with the C-terminal amino acid of such vertebrate G protein, wherein such number equals the number of amino acids deleted. In other embodiments, the chimeric G protein has an amino acid sequence substantially the same as the amino acid sequence shown in (a) Figure 2, *C. elegans*  $G\alpha_{q/z5}$  (SEQ ID NO: 1); (b) Figure 2, *C. elegans*  $G\alpha_{q/z9}$  (SEQ ID NO: 2); (c) Figure 2, *C. elegans*  $G\alpha_{q/s9}$  (SEQ ID NO: 3); (d) Figure 2, *C. elegans*  $G\alpha_{q/s21}$  (SEQ ID NO: 4); (e) Figure 2, *C. elegans*  $G\alpha_{q/i3(5)}$  (SEQ ID NO: 5); or (f) Figure 2, *D. melanogaster*  $G\alpha_{q/zs}$  (SEQ ID NO: 41).

In one embodiment of any of the aforementioned processes, the cell is an insect cell. In another embodiment, the cell is a mammalian cell. In one embodiment, the mammalian cell is nonneuronal in origin. In further embodiments, the nonneuronal cell is a COS-7 cell, 293 human embryonic kidney cell, a CHO cell, a NIH-3T3 cell, a mouse Y1 cell, or a LM(tk-) cell.

The invention provides a process for determining whether a chemical compound is a ligand for a mammalian G protein-coupled receptor which comprises contacting cells transfected with and expressing DNA encoding a chimeric G protein and expressing DNA encoding a mammalian G protein-coupled receptor, with the compound under conditions permitting the activation of the mammalian G protein-coupled receptor, and detecting an increase in mammalian G protein-coupled receptor activity, so as to thereby determine whether the compound activates the mammalian G protein-coupled receptor and is a ligand for the mammalian G protein-coupled receptor.

The invention further provides a process for determining whether a chemical compound is a ligand for a mammalian G protein-coupled receptor which comprises contacting a membrane preparation from cells transfected with and expressing DNA encoding a chimeric G protein and expressing DNA encoding a mammalian G protein-coupled receptor, with the compound under conditions permitting the activation of the mammalian G protein-coupled receptor, and detecting an increase in mammalian G protein-coupled receptor activity, so as to thereby determine whether the compound activates the mammalian G protein-coupled receptor and is a ligand for the mammalian G protein-coupled receptor.

The invention also provides a process for determining whether a chemical compound is a ligand for a mammalian G protein-coupled receptor which comprises contacting cells producing a second messenger response, expressing the DNA encoding the mammalian G protein-coupled receptor, and expressing the DNA encoding a chimeric G protein, wherein such cells do

not normally express the DNA encoding the chimeric G protein, with the chemical compound under conditions suitable for activation of the mammalian G protein-coupled receptor, and measuring the second messenger response in the presence and in the absence of the chemical compound, a change in the second messenger response in the presence of the chemical compound indicating that the compound activates the mammalian G protein-coupled receptor and is a ligand for the mammalian G protein-coupled receptor.

In one embodiment of the aforementioned process, the second messenger response is a  $G\alpha_q$  second messenger response. In one embodiment, the  $G\alpha_q$  second messenger response comprises intracellular calcium levels and the change in second messenger is an increase in the measure of intracellular calcium. In one embodiment, the measure of intracellular calcium levels is made by chloride current readings. In other embodiments, the measure of intracellular calcium is made by fluorescence readings, luminescence readings, electrophysiological readings, or through the detection of a reporter protein under the transcriptional control of a calcium-responsive promoter element.

In addition, the invention provides a process of screening a plurality of chemical compounds not known to activate a mammalian G protein-coupled receptor to identify a ligand for the mammalian G protein-coupled receptor which comprises:

- (a) contacting cells transfected with and expressing DNA encoding a chimeric G protein and expressing DNA encoding a mammalian G protein-coupled receptor with the plurality of compounds not

known to activate the mammalian G protein-coupled receptor, under conditions permitting activation of the mammalian G protein-coupled receptor;

5

(b) determining whether the activity of the mammalian G protein-coupled receptor is increased in the presence of one or more of the compounds; and if so

10

(c) separately determining whether the activation of the mammalian G protein-coupled receptor is increased by any compound included in the plurality of compounds, so as to thereby identify each compound which activates the mammalian G protein-coupled receptor and is a ligand for the mammalian G protein-coupled receptor.

15

20

The invention also provides a process for determining whether a chemical compound is a ligand for a mammalian G protein-coupled receptor, which comprises separately contacting membrane preparations from cells transfected with and expressing DNA encoding a chimeric G protein and expressing DNA encoding a mammalian G protein-coupled receptor with both the compound and [<sup>35</sup>S]GTPγS, and with only [<sup>35</sup>S]GTPγS, under conditions permitting the activation of the mammalian G protein-coupled receptor, and detecting [<sup>35</sup>S]GTPγS binding to the membrane preparation and an increase in [<sup>35</sup>S]GTPγS binding in the presence of the compound indicating that the chemical compound activates the mammalian G protein-coupled receptor and is a ligand for the mammalian G protein-coupled receptor.

25

30

35

In addition, the invention provides a process for determining whether a chemical compound is a ligand for the mammalian G protein-coupled receptor, which comprises contacting cells transfected with and  
5 expressing DNA encoding a chimeric G protein and expressing DNA encoding a mammalian G protein-coupled receptor with a compound, under conditions permitting the activation of the mammalian G protein-coupled receptor, and detecting changes in receptor active  
10 state conformation as manifested by changes in receptor/G protein heterotrimer association/dissociation in the presence of the compound indicating that the chemical compound activates the mammalian G protein-coupled receptor  
15 and is a ligand for the mammalian G protein-coupled receptor.

The invention further provides a process for identifying a ligand for a mammalian G protein-coupled receptor which comprises contacting cells  
20 transfected with and expressing DNA encoding a chimeric G protein and expressing DNA encoding a mammalian G protein-coupled receptor, wherein such cells do not normally express the DNA encoding the  
25 chimeric G protein, with the compound under conditions suitable for binding, and detecting specific binding of the chemical compound to the mammalian G protein-coupled receptor, indicating that the compound is a ligand for the mammalian G protein-coupled  
30 receptor.

The inventions still further provides a process for identifying a chemical compound which specifically  
35 binds to a mammalian G protein-coupled receptor which comprises contacting a membrane preparation from cells transfected with and expressing DNA encoding a

chimeric G protein and expressing DNA encoding a mammalian G protein-coupled receptor, wherein such cells do not normally express the DNA encoding the chimeric G protein, with the compound under conditions suitable for binding, and detecting specific binding of the chemical compound to the mammalian G protein-coupled receptor, indicating that the compound is a ligand for the mammalian G protein-coupled receptor.

In one embodiment of any of the aforementioned processes, the DNA encoding the mammalian G protein-coupled receptor is endogenous to the cell. In another embodiment, the DNA encoding the mammalian G protein-coupled receptor is transfected into the cell.

In one embodiment of any of the aforementioned processes, the chimeric G protein comprises an invertebrate G $\alpha$ q G protein from which at least five, but not more than twenty-one, contiguous amino acids beginning with the C-terminal amino acid have been deleted and replaced by a number of contiguous amino acids present in a vertebrate G protein beginning with the C-terminal amino acid of such vertebrate G protein, wherein such number equals the number of amino acids deleted. In another embodiment, the chimeric G protein comprises an invertebrate G $\alpha$ q G protein from which at least five, but not more than twenty-one, contiguous amino acids beginning with the C-terminal amino acid have been deleted and replaced by a number of contiguous amino acids present in a vertebrate G $\alpha$ z protein beginning with the C-terminal amino acid of such vertebrate G $\alpha$ z protein, wherein such number equals the number of amino acids deleted.

In another embodiment, the chimeric G protein comprises an invertebrate  $G\alpha_q$  G protein from which at least five, but not more than twenty-one, contiguous amino acids beginning with the C-terminal amino acid have been deleted and replaced by a number of contiguous amino acids present in a vertebrate  $G\alpha_s$  protein beginning with the C-terminal amino acid of such vertebrate  $G\alpha_s$  protein, wherein such number equals the number of amino acids deleted. In another embodiment, the chimeric G protein comprises an invertebrate  $G\alpha_q$  G protein from which at least five, but not more than twenty-one, contiguous amino acids beginning with the C-terminal amino acid have been deleted and replaced by a number of contiguous amino acids present in a vertebrate  $G_i3$  protein beginning with the C-terminal amino acid of such vertebrate  $G_i3$  protein, wherein such number equals the number of amino acids deleted.

In another embodiment, the chimeric G protein comprises an *Caenorhabditis elegans*  $G\alpha_q$  G protein from which at least five, but not more than twenty-one, contiguous amino acids beginning with the C-terminal amino acid have been deleted and replaced by a number of contiguous amino acids present in a vertebrate G protein beginning with the C-terminal amino acid of such vertebrate G protein, wherein such number equals the number of amino acids deleted. In other embodiments, the chimeric G protein comprises a *Drosophila melanogaster*  $G\alpha_q$  G protein, a *Limulus polyphemus*  $G\alpha_q$  G protein, a *Patinopecten yessoensis*  $G\alpha_q$  G protein, a *Loligo forbesi*  $G\alpha_q$  G protein, a *Homarus americanus*  $G\alpha_q$  G protein, a *Lymnaea stagnalis*  $G\alpha_q$  G protein, a *Geodia cydonium*  $G\alpha_q$  G protein, or a *Dictyostelium discoideum*  $G\alpha_4$  G protein, from which at

least five, but not more than twenty-one, contiguous amino acids beginning with the C-terminal amino acid have been deleted and replaced by a number of contiguous amino acids present in a vertebrate G protein beginning with the C-terminal amino acid of such vertebrate G protein, wherein such number equals the number of amino acids deleted. In other embodiments, the chimeric G protein has an amino acid sequence substantially the same as the amino acid sequence shown in (a) Figure 2, *C. elegans*  $G\alpha_{q/z5}$  (SEQ ID NO: 1); (b) Figure 2, *C. elegans*  $G\alpha_{q/z9}$  (SEQ ID NO: 2); (c) Figure 2, *C. elegans*  $G\alpha_{q/s9}$  (SEQ ID NO: 3); (d) Figure 2, *C. elegans*  $G\alpha_{q/s21}$  (SEQ ID NO: 4); (e) Figure 2, *C. elegans*  $G\alpha_{q/i3(5)}$  (SEQ ID NO: 5); or (f) Figure 2, *D. melanogaster*  $G\alpha_{q/zs}$  (SEQ ID NO: 41).

In one embodiment of any of the aforementioned processes, the cell is an insect cell. In another embodiment, the cell is a mammalian cell. In one embodiment, the mammalian cell is nonneuronal in origin. In further embodiments, the nonneuronal cell is a COS-7 cell, 293 human embryonic kidney cell, a CHO cell, a NIH-3T3 cell, a mouse Y1 cell, or a LM(tk-) cell.

The invention also provides a process of screening a plurality of independent clones not known to include a clone encoding a mammalian G protein-coupled receptor, to identify and isolate a clone encoding a mammalian G protein-coupled receptor, which comprises:

(a) contacting cells transfected with and expressing DNA encoding a chimeric G protein and expressing

DNA encoding a plurality of independent clones with a ligand, under conditions permitting activation of a mammalian G protein-coupled receptor;

5

(b) determining whether the ligand activates the cells expressing the plurality of independent clones and the chimeric G protein; and if so

10

(c) isolating the single clone which expresses the mammalian G protein-coupled receptor activated by the ligand, so as to thereby identify any clone included in the plurality of clones as encoding a mammalian G protein-coupled receptor.

15

The invention further provides a process of screening a plurality of independent clones not known to include a clone encoding a mammalian G protein-coupled receptor, to identify and isolate a clone encoding a mammalian G protein-coupled receptor, which comprises:

20

(a) contacting cells transfected with and expressing DNA encoding a chimeric G protein and expressing DNA encoding a plurality of independent clones with a ligand, under conditions permitting specific binding to a mammalian G protein-coupled receptor;

25

30

(b) determining whether the ligand specifically binds to the cells expressing the plurality of independent clones and the chimeric G protein; and if so

35

(c) isolating the single clone which expresses the mammalian G protein-coupled receptor which specifically binds to the ligand, so as to thereby identify any clone included in the plurality of clones as encoding a mammalian G protein-coupled receptor.

In one embodiment of the aforementioned processes, the DNA encoding the plurality of independent clones is endogenous to the cell. In another embodiment, the DNA encoding the plurality of independent clones is transfected into the cell.

In one embodiment of the aforementioned processes, the chimeric G protein comprises an invertebrate G $\alpha$ q G protein from which at least five, but not more than twenty-one, contiguous amino acids beginning with the C-terminal amino acid have been deleted and replaced by a number of contiguous amino acids present in a vertebrate G protein beginning with the C-terminal amino acid of such vertebrate G protein, wherein such number equals the number of amino acids deleted. In another embodiment, the chimeric G protein comprises an invertebrate G $\alpha$ q G protein from which at least five, but not more than twenty-one, contiguous amino acids beginning with the C-terminal amino acid have been deleted and replaced by a number of contiguous amino acids present in a vertebrate G $\alpha$ z protein beginning with the C-terminal amino acid of such vertebrate G $\alpha$ z protein, wherein such number equals the number of amino acids deleted. In another embodiment, the chimeric G protein comprises an invertebrate G $\alpha$ q G protein from which at least five, but not more than twenty-one, contiguous amino acids beginning with the C-terminal amino acid have been

deleted and replaced by a number of contiguous amino acids present in a vertebrate  $G\alpha s$  protein beginning with the C-terminal amino acid of such vertebrate  $G\alpha s$  protein, wherein such number equals the number of amino acids deleted. In another embodiment, the chimeric G protein comprises an invertebrate  $G\alpha q$  G protein from which at least five, but not more than twenty-one, contiguous amino acids beginning with the C-terminal amino acid have been deleted and replaced by a number of contiguous amino acids present in a vertebrate  $G\alpha i3$  protein beginning with the C-terminal amino acid of such vertebrate  $G\alpha i3$  protein, wherein such number equals the number of amino acids deleted.

In another embodiment, the chimeric G protein comprises an *Caenorhabditis elegans*  $G\alpha q$  G protein from which at least five, but not more than twenty-one, contiguous amino acids beginning with the C-terminal amino acid have been deleted and replaced by a number of contiguous amino acids present in a vertebrate G protein beginning with the C-terminal amino acid of such vertebrate G protein, wherein such number equals the number of amino acids deleted. In other embodiments, the chimeric G protein comprises a *Drosophila melanogaster*  $G\alpha q$  G protein, a *Limulus polyphemus*  $G\alpha q$  G protein, a *Patinopecten yessoensis*  $G\alpha q$  G protein, a *Loligo forbesi*  $G\alpha q$  G protein, a *Homarus americanus*  $G\alpha q$  G protein, a *Lymnaea stagnalis*  $G\alpha q$  G protein, a *Geodia cydonium*  $G\alpha q$  G protein, or a *Dictyostelium discoideum*  $G\alpha_4$  G protein, from which at least five, but not more than twenty-one, contiguous amino acids beginning with the C-terminal amino acid have been deleted and replaced by a number of contiguous amino acids present in a vertebrate G protein beginning with the C-terminal amino acid of

such vertebrate G protein, wherein such number equals the number of amino acids deleted. In other embodiments, the chimeric G protein has an amino acid sequence substantially the same as the amino acid sequence shown in (a) Figure 2, *C. elegans*  $G\alpha_{q/z5}$  (SEQ ID NO: 1); (b) Figure 2, *C. elegans*  $G\alpha_{q/z9}$  (SEQ ID NO: 2); (c) Figure 2, *C. elegans*  $G\alpha_{q/s9}$  (SEQ ID NO: 3); (d) Figure 2, *C. elegans*  $G\alpha_{q/s21}$  (SEQ ID NO: 4); (e) Figure 2, *C. elegans*  $G\alpha_{q/i3(5)}$  (SEQ ID NO: 5); or (f) Figure 2, *D. melanogaster*  $G\alpha_{q/zs}$  (SEQ ID NO: 41).

In one embodiment of the aforementioned processes, the cell is an insect cell. In another embodiment, the cell is a mammalian cell. In one embodiment, the mammalian cell is nonneuronal in origin. In further embodiments, the nonneuronal cell is a COS-7 cell, 293 human embryonic kidney cell, a CHO cell, a NIH-3T3 cell, a mouse Y1 cell, or a LM(tk-) cell.

The invention provides a process for making a composition of matter which specifically binds to a mammalian G protein-coupled receptor which comprises identifying a chemical compound using any of the aforementioned processes and then synthesizing the chemical compound or a novel structural and functional analog or homolog thereof. The invention also provides a process for preparing a composition which comprises admixing a carrier and a pharmaceutically effective amount of a chemical compound identified by any of the aforementioned processes or a novel structural and functional analog or homolog thereof.

GPCRs that can be used with the invention include, but are not limited to, neuropeptide FF receptors, e.g., human NPFF1 (ATCC Accession number 203605) and human NPFF2 (ATCC Accession number 203255). Plasmid pcDNA3.1-hNPFF1 and plasmid pCDNA3.1-hNPFF2b were deposited on January 21, 1999 and September 22, 1998, respectively, with the American Type Culture Collection (ATCC), 10801 University Blvd., Manassas, Virginia 20110-2209, U.S.A. under the provisions of the Budapest Treaty for the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure and were accorded ATCC Accession Nos. 203605 and 203255, respectively.

Further GPCRs that can be used with the invention include, but are not limited to, serotonin receptors, e.g., human 5HT1D (U.S. Patent No. 5,155,218, the disclosure of which is hereby incorporated by reference in its entirety into this application), rabbit 5HT1D (Harwood, G. et al., 1995), human 5HT7 (ATCC Accession number 75332), human 5HT1E (U.S. Patent No. 5,476,782, the disclosure of which is hereby incorporated by reference in its entirety into this application), human 5HT1F (U.S. Patent No. 5,360,735, the disclosure of which is hereby incorporated by reference in its entirety into this application), human 5HT5A (Plassat et al., 1992), human 5HT5B (Matthes et al., 1993), human 5HT1B (U.S. Patent No. 5,155,218, the disclosure of which is hereby incorporated by reference in its entirety into this application), human 5HT4 (U.S. Patent No. 5,766,879, the disclosure of which is hereby incorporated by reference in its entirety into this application), human 5HT6 (Kohen et al., 1996), and human 5HT1A (Kobilka et al., 1987). Plasmid pcEXV-5HT<sub>4B</sub> was deposited on October 20, 1992 with the

American Type Culture Collection (ATCC), 10801 University Blvd., Manassas, Virginia 20110-2209, U.S.A. under the provisions of the Budapest Treaty for the International Recognition of the Deposit of  
5 Microorganisms for the Purposes of Patent Procedure and was accorded ATCC Accession No. 75332.

Further GPCRs that can be used with the invention include, but are not limited to, dopamine receptors,  
10 e.g., human D1, human D2, human D3, and human D5 (U.S. Patent No. 5,780,485, the disclosure of which is hereby incorporated by reference in its entirety into this application), and alpha adrenergic receptors, e.g., human  $\alpha$ 1A adr, human  $\alpha$ 2C adr, human  
15  $\alpha$ 2B adr, human  $\alpha$ 2A adr (U.S. Patent No. 5,780,485, the disclosure of which is hereby incorporated by reference in its entirety into this application), and human  $\beta$ 2 adr (Dixon et al., 1986).

Further GPCRs that can be used with the invention include, but are not limited to, galanin receptors, e.g., human GALR1 (Habert-Ortoli et al., 1994), rat GALR1 (Burgevin et al., 1995), human GALR2 (ATCC Accession No. 97851), rat GALR2 (ATCC Accession No.  
20 97426), human GALR3 (ATCC Accession No. 97827), and rat GALR3 (ATCC Accession No. 97826). Plasmids pEXJ-hGalR3 and pEXJ-rGALR3T were deposited on December 17, 1996, with the American Type Culture Collection (ATCC), 10801 University Blvd., Manassas, Virginia  
25 20110-2209, U.S.A. under the provisions of the Budapest Treaty for the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure and were accorded ATCC Accession Nos. 97827 and 97826, respectively. Plasmids BO39 and  
30 K985 were deposited on January 15, 1997 and January 24, 1996, respectively, with the American Type  
35

Culture Collection (ATCC), 10801 University Blvd., Manassas, Virginia 20110-2209, U.S.A. under the provisions of the Budapest Treaty for the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure and were accorded ATCC Accession Nos. 97851 and 97426, respectively.

Further GPCRs that can be used with the invention include, but are not limited to, neuropeptide Y receptors, e.g., human Y1 (Larhammar et al., 1992), rat Y1 (Eva et al., 1990), human Y2 (U.S. Patent No. 5,545,549, the disclosure of which is hereby incorporated by reference in its entirety into this application), human Y4 (U.S. Patent No. 5,516,653, the disclosure of which is hereby incorporated by reference in its entirety into this application), rat Y4 (ATCC Accession No. 75984), human Y5 (U.S. Patent No. 5,602,024, the disclosure of which is hereby incorporated by reference in its entirety into this application), and rat Y5 (U.S. Patent No. 5,602,024, the disclosure of which is hereby incorporated by reference in its entirety into this application). Plasmid pcEXV-rY4 was deposited on December 21, 1994 with the American Type Culture Collection (ATCC), 10801 University Blvd., Manassas, Virginia 20110-2209, U.S.A. under the provisions of the Budapest Treaty for the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure and were accorded ATCC Accession No. 75984.

Further GPCRs that can be used with the invention include, but are not limited to, neurotensin receptors, e.g., rat NTR1 (Tanaka et al., 1990); glucagon-like peptide receptors, e.g., human GLP-1 (Dillon et al., 1993); kappa opioid receptors, e.g.,

human kappa (Mansson et al., 1994); and melanin  
concentrating hormone receptors, e.g., human MCH  
(ATCC Accession No. 203197). Plasmid pEXJ.HR-TL231  
was deposited on September 17, 1998 with the American  
5 Type Culture Collection (ATCC), 10801 University  
Blvd., Manassas, Virginia 20110-2209, U.S.A. under  
the provisions of the Budapest Treaty for the  
International Recognition of the Deposit of  
Microorganisms for the Purposes of Patent Procedure  
10 and were accorded ATCC Accession No. 203197.

The invention will be better understood from the  
Experimental Details which follow. However, one  
skilled in the art will readily appreciate that the  
15 specific methods and results discussed are merely  
illustrative of the invention as described more fully  
in the claims which follow thereafter.

## Experimental Details

### Materials and Methods

5     Cloning of the gene encoding *C. elegans*  $G\alpha_q$   
 The gene for wild-type *C. elegans*  $G\alpha_q$  was obtained by  
 PCR amplification of a mixed stage *C. elegans* cDNA  
 library (Stratagene, #937006) with the primers RP65  
 and RP66 (Table 1). The resulting product was cloned  
 10     into the vector pcDNA 3.1 Zeo (Invitrogen) at the  
 KpnI and XbaI sites. DNA sequence analysis  
 demonstrated that the clone designated R48 was  
 identical to that of the *C. elegans*  $G\alpha_q$  gene  
 deposited in Genbank (accession number AF003739).

15     Cloning of the gene encoding *D. melanogaster*  $G\alpha_q$   
 The gene for wild-type *D. melanogaster*  $G\alpha_q$  (isoform  
 3) was obtained by PCR amplification of *D.*  
*melanogaster* cDNA using primers RP203 and RP204  
 20     (Table 1). The resulting product was cloned into  
 pcDNA3.1 (Invitrogen) at the KpnI and EcoRI sites.  
 DNA sequence analysis demonstrated that the clone  
 designated R129 encoded a protein identical to that  
 of the *D. melanogaster*  $G\alpha_{q3}$  gene deposited in Genbank  
 25     (accession number P54400).

30     Cloning of genes encoding human  $G\alpha_q$   
 The sequence of human  $G\alpha_q$  was confirmed by automated  
 sequence analysis. Except for the substitution of a  
 single amino acid at position 171 (Ala  $\rightarrow$  Ser) in a  
 highly non-conserved region of the protein, the  
 deduced amino acid sequence is identical to that of  
 Accession Number L76256. This sequence was used to  
 generate the various human chimerae described  
 35     throughout this application, except as noted in Table

9. A second human  $G\alpha_q$  clone was obtained using standard PCR-based techniques that has a sequence identical to Genbank entry L76256. As expected, chimerae utilizing these two independently derived human  $G\alpha_q$  sequences were found to be functionally indistinguishable in parallel assays (Table 9), using the dopamine D1 receptor as an example.

#### Construction of G protein cDNAs with chimeric 3' ends

Most of the chimeric G protein cDNAs were made by a PCR approach (Table 2). In each case, the designated primers were used to amplify the 3' end of the appropriate template to generate a chimeric PCR product. This product was then subcloned back into wild-type human, *D. melanogaster*, or *C. elegans*  $G\alpha_q$ , as appropriate, to generate a full-length chimeric gene. All PCR derived sequences were verified by sequence analysis. Two chimeras (Table 3) were constructed using the QuikChange site-directed mutagenesis kit (Stratagene, #200518). For these clones, the sequence of the entire coding region was verified. Examples of chimeric G proteins used in the present application are depicted in Figure 2.

**TABLE 1.** Primer sequences used in the preparation of chimeric G protein genes

PRIMER	SEQUENCE
MJ177	5' GAATATGATGGACCCAGAGAGATG 3' (SEQ ID NO: 19)
MJ178	5' GATCCTCGAGTTAGCACAGTCCGATGTACTTCAGGTTC AACTGGAGGATGGT 3' (SEQ ID NO: 20)
MJ180	5' GATCCTCGAGTTAGTACAGTCCGCATCCCTTCAGGTTCA ACTGGAGGATGGT 3' (SEQ ID NO: 21)
MJ193	5' GATCCTCGAGTTAGTAAAGCCCACATTCCTTCAGGTTC AACTGGAGGATGGT 3' (SEQ ID NO: 22)

MJ194	5' GATCCTCGAGTTAGAGCAGCTCGTATTGCTTCAGGTTCA ACTGGAGGATGGT 3' (SEQ ID NO: 23)
MJ197	5' GGAAAAAAGCGGCCGCTTAAACAGTCCGCAGTCC TTCAGGTTCAACTGGAGGATGGT 3' (SEQ ID NO: 24)
RP65	5' GGGGTACCGCCGCCATGGCCTGCTGTTTATCC 3' (SEQ ID NO: 25)
RP66	5' GCTCTAGATTACACCAAGTTGTACTCCTTCAGATT 3' (SEQ ID NO: 26)
RP80	5' CTCTCCGATCTCCGACGGCTG 3' (SEQ ID NO: 27)
RP83	5' TTCTACAGCATAATCTGAAGTATATCGGTTTGTGTTAATCT AGAGGGCCCGTTTAAACCCGCTG 3' (SEQ ID NO: 28)
RP84	5' CAGCGGGTTTAAACGGGGCCCTCTAGATTAACACAAACCGAT ATACTTCAGATTATGCTGTAGAA 3' (SEQ ID NO: 29)
RP85	5' CAGCATAATCTGAAGGAGTGTGGATTGTACTAATCTAGA GGGCCCCG 3' (SEQ ID NO: 30)
RP86	5' CGGGCCCTCTAGATTAGTACAATCCACACTCCTTCAG ATTATGCTG 3' (SEQ ID NO: 31)
RP116	5' GGAAAAAAGCGGCCGCTTAGAGCAGCTCGTATTGC CTCAGGTGCATCTGGAGGATGGTGTCTTGACGG 3' (SEQ ID NO: 32)
RP142	5' GCTCTAGATTAGAGCAGCTCGTATTGCCTCAGGTGCATCTG TAGAATTGTGTCTTTGACGGCG 3' (SEQ ID NO: 33)
RP168	5' GCTCTAGATTAACATAGCCCTATGTATTTTAGATTATTCTG TAGAATTGTGTCTTTGACGGCG 3' (SEQ ID NO: 34)
RP177	5' GCTCTAGATTAGAGCAGCTCGTATTGCCTCAGGTGCATACG TTGAATAATGTCACGACAGTCATTAAAAACACGCCGAATGT TTCCGTATCAGTCGC 3' (SEQ ID NO: 35)

RP203	5' CGGGGTACCCCGGTTAGCATGGAGTGCTGTTTATCG 3' (SEQ ID NO: 42)
RP204	5' CCGGAATTCGCGTTAGACCAAATTATATTCCTTAAGGTTC 3' (SEQ ID NO: 43)
RP218	5' GAGCATCGATTACGAGACCGTTACC 3' (SEQ ID NO: 44)
RP219	5' CGGAATTCTTAGCACAGTCCGATGTACTTAAGGTTTCGATTG CAGAATTGTGTC 3' (SEQ ID NO: 45)

**TABLE 2.** Primer pairs used to generate chimeric genes  
by PCR

CHIMERA	PCR TEMPLATE	PRIMERS
Human $G\alpha_{q/z5}$	$hG\alpha_q$	MJ177 / MJ178
Human $G\alpha_{q/i2(5)}$	$hG\alpha_q$	MJ177 / MJ197
Human $G\alpha_{q/i3(5)}$	$hG\alpha_q$	MJ177 / MJ193
Human $G\alpha_{q/o5}$	$hG\alpha_q$	MJ177 / MJ180
Human $G\alpha_{q/s5}$	$hG\alpha_q$	MJ177 / MJ194
Human $G\alpha_{q/s9}$	$hG\alpha_q$	MJ177 / RP116
<i>C.elegans</i> $G\alpha_{q/s9}$	R48	RP80 / RP142
<i>C. elegans</i> $G\alpha_{q/s21}$	R48	RP80 / RP177
<i>C. elegans</i> $G\alpha_{q/z9}$	R48	RP80 / RP168
<i>D. melanogaster</i> $G\alpha_{q/z}$	R129	RP218/ RP219

**TABLE 3.** Primer pairs used to generate chimeric genes  
using mutagenesis

CHIMERA	TEMPLATE	PRIMERS
<i>C.elegans</i> $G\alpha_{q/i3(5)}$	R48	RP85 / RP86
<i>C.elegans</i> $G\alpha_{q/z5}$	R48	RP83 / RP84

### General methods of transfecting cells

Methods of transfecting cells, e.g. mammalian cells, with such nucleic acid encoding a GPCR to obtain cells in which the GPCR is expressed on the surface of the cell are well known in the art. (See, for example, U.S. Patent Nos. 5,053,337; 5,155,218; 5,360,735; 5,472,866; 5,476,782; 5,516,653; 5,545,549; 5,556,753; 5,595,880; 5,602,024; 5,639,652; 5,652,113; 5,661,024; 5,766,879; 5,786,155; and 5,786,157, the disclosures of which are hereby incorporated by reference in their entireties into this application.) The cells may be additionally transfected with nucleic acid encoding chimeric G proteins to obtain cells in which both the GPCR and the chimeric G proteins are expressed in the cell.

Such transfected cells may also be used to test compounds and screen compound libraries to obtain compounds which bind receptors as well as compounds which activate or inhibit activation of functional responses in such cells, and therefore are likely to do so in vivo. (See, for example, U.S. Patent Nos. 5,053,337; 5,155,218; 5,360,735; 5,472,866; 5,476,782; 5,516,653; 5,545,549; 5,556,753; 5,595,880; 5,602,024; 5,639,652; 5,652,113; 5,661,024; 5,766,879; 5,786,155; and 5,786,157, the disclosures of which are hereby incorporated by reference in their entireties into this application.)

### Host cells

A broad variety of host cells can be used to study heterologously expressed proteins. These cells include but are not limited to mammalian cell lines such as; Cos-7, CHO, LM(*tk*<sup>-</sup>), HEK293, etc.; insect cell lines such as; Sf9, Sf21, etc.; amphibian cells

such as *Xenopus* oocytes; assorted yeast strains; assorted bacterial cell strains; and others. Culture conditions for each of these cell types is specific and is known to those familiar with the art.

5

#### Transient expression

DNA encoding proteins to be studied can be transiently expressed in a variety of mammalian, insect, amphibian, yeast, bacterial and other cells lines by several transfection methods including but not limited to: calcium phosphate-mediated, DEAE-dextran mediated; liposomal-mediated, viral-mediated, electroporation-mediated, and microinjection delivery. Each of these methods may require optimization of assorted experimental parameters depending on the DNA, cell line, and the type of assay to be subsequently employed.

10

15

#### Stable expression

Heterologous DNA can be stably incorporated into host cells, causing the cell to perpetually express a foreign protein. Methods for the delivery of the DNA into the cell are similar to those described above for transient expression but require the cotransfection of an ancillary gene to confer drug resistance on the targeted host cell. The ensuing drug resistance can be exploited to select and maintain cells that have taken up the DNA. An assortment of resistance genes are available including but not restricted to neomycin, kanamycin, and hygromycin.

20

25

30

#### Mammalian cell tissue culture and transfection.

COS-7 cells were cultured in 225 cm<sup>2</sup> flasks in Dulbecco's Modified Eagle Medium (DMEM) with supplements (10% bovine calf serum, 4 mM glutamine,

35

100 units/ml penicillin and 100 µg/ml streptomycin) at 37°C, 5% CO<sub>2</sub>. Stock plates of COS-7 cells were trypsinized and split 1:6 every 3-4 days.

5 GPCR and chimeric G protein cDNAs were transiently transfected into COS-7 cells in 150 cm<sup>2</sup> flasks by the DEAE-dextran method (Cullen, 1987), using a total of 20 µg of DNA/ ~ 7 x 10<sup>6</sup> cells. For evaluating the function of a single chimeric G protein, the standard  
10 cDNA transfection ratio was 1:1 (10 µg GPCR cDNA and 10 µg chimeric G protein cDNA). For evaluating the function of a mixture of chimeric G proteins, the standard cDNA transfection ratio was 8:1:1 (16 µg GPCR cDNA, 2 µg Gα<sub>q/z</sub> cDNA, 2 µg Gα<sub>q/s</sub> cDNA).

15 Membrane preparations

Cell membranes expressing the heterologously expressed proteins of this invention are useful for certain types of assays including but not restricted  
20 to ligand binding assays, GTPγS binding assays, and others. The specifics of preparing such cell membranes may in some cases be determined by the nature of the ensuing assay but typically involve harvesting whole cells and disrupting the cell pellet  
25 by sonication in ice cold buffer (e.g. 20 mM Tris-HCl, 5 mM EDTA, pH 7.4). The resulting crude cell lysate is cleared of cell debris by low speed centrifugation at 200xg for 5 min at 4°C. The cleared supernatant is then centrifuged at 40,000xg  
30 for 20 min at 4°C, and the resulting membrane pellet is washed by suspending in ice cold buffer and repeating the high speed centrifugation step. The final washed membrane pellet is resuspended in assay buffer. Protein concentrations are determined by the  
35 method of Bradford (1976) using bovine serum albumin

as a standard. The membranes may be used immediately or frozen for later use.

#### Generation of baculovirus

5 The coding region of DNA encoding the human receptor and the chimeric G protein disclosed herein may be separately subcloned into pBlueBacIII into existing restriction sites or sites engineered into sequences 5' and 3' to the coding region of the polypeptides.

10 To generate baculovirus, 0.5  $\mu$ g of viral DNA (BaculoGold) and 3  $\mu$ g of DNA construct encoding a polypeptide may be co-transfected into  $2 \times 10^6$  *Spodoptera frugiperda* insect Sf9 cells by the calcium phosphate co-precipitation method, as outlined by

15 Pharmingen (in "Baculovirus Expression Vector System: Procedures and Methods Manual"). The cells are then incubated for 5 days at 27°C.

20 The supernatant of the co-transfection plate may be collected by centrifugation and the recombinant virus plaque purified. The procedure to infect cells with virus, to prepare stocks of virus and to titer the virus stocks are as described in Pharmingen's manual.

#### Binding assays

25 Labeled ligands are placed in contact with either membrane preparations or intact cells expressing the chimeric G protein and receptor of interest in multi-well microtiter plates, together with unlabeled

30 compounds, and binding buffer. Binding reaction mixtures are incubated for times and temperatures determined to be optimal in separate equilibrium binding assays. The reaction is stopped by filtration through GF/B filters, using a cell

35 harvester, or by directly measuring the bound ligand. If the ligand was labeled with a radioactive isotope

such as  $^3\text{H}$ ,  $^{14}\text{C}$ ,  $^{125}\text{I}$ ,  $^{35}\text{S}$ ,  $^{32}\text{P}$ ,  $^{33}\text{P}$ , etc., the bound ligand may be detected by using liquid scintillation counting, scintillation proximity, or any other method of detection for radioactive isotopes. If the

5 the ligand was labeled with a fluorescent compound, the bound labeled ligand may be measured by methods such as, but not restricted to, fluorescence intensity, time resolved fluorescence, fluorescence polarization, fluorescence transfer, or fluorescence

10 correlation spectroscopy. In this manner, agonist or antagonist compounds that bind to the receptor may be identified as they inhibit the binding of the labeled ligand to the membrane protein or intact cells expressing the said receptor. Non-specific binding

15 is defined as the amount of labeled ligand remaining after incubation of membrane protein in the presence of a high concentration (e.g., 100-1000  $\times K_D$ ) of unlabeled ligand. In equilibrium saturation binding assays membrane preparations or intact cells

20 transfected with the chimeric G protein and GPCR are incubated in the presence of increasing concentrations of the labeled compound to determine the binding affinity of the labeled ligand. The binding affinities of unlabeled compounds may be

25 determined in equilibrium competition binding assays, using a fixed concentration of labeled compound in the presence of varying concentrations of the displacing ligands.

### 30 Functional assays

Cells expressing the chimeric G protein DNA of this invention and a GPCR may be used to screen for ligands to the GPCR using functional assays. Once a ligand is identified, the same assays may be used to

35 identify agonists or antagonists of the GPCR that may be employed for a variety of therapeutic purposes.

It is well known to those in the art that the over-expression of a G protein-coupled receptor can result in the constitutive activation of intracellular signaling pathways. In the same manner, over-expression of an orphan receptor and a chimeric G protein in any cell line as described above, can result in the activation of the functional responses described below, and any of the assays herein described can be used to screen for both agonist and antagonist ligands of the orphan receptor.

A wide spectrum of assays can be employed to screen for the presence of orphan receptor ligands or to identify agonists or antagonists of a characterized GPCR. These assays range from traditional measurements of total inositol phosphate accumulation, cAMP levels, intracellular calcium mobilization, and potassium currents, for example; to systems measuring these same second messengers, but which have been modified or adapted to be of higher throughput, more generic, and more sensitive; to cell based assays reporting more general cellular events resulting from receptor activation such as metabolic changes, differentiation, cell division/proliferation. Description of several such assays follow.

#### Cyclic AMP (cAMP) assay

Elevation of intracellular  $\text{Ca}^{++}$  can modulate the activity of adenylyl cyclases via  $\text{Ca}^{++}$ -dependent calmodulin (Sunahara et al., 1996). The receptor-mediated stimulation or inhibition of cyclic AMP (cAMP) formation may be assayed in cells expressing a GPCR and chimeric G protein. Cells are plated in 96-well plates or other vessels and preincubated in a buffer such as HEPES buffered saline (NaCl (150 mM),

CaCl<sub>2</sub> (1 mM), KCl (5 mM), glucose (10 mM)) supplemented with a phosphodiesterase inhibitor such as 5mM theophylline, with or without protease inhibitor cocktail for 20 min at 37°C, in 5% CO<sub>2</sub>. A typical inhibitor cocktail contains 2 µg/ml aprotinin, 0.5 mg/ml leupeptin, and 10 µg/ml phosphoramidon. Test compounds are added with or without 10 mM forskolin and incubated for an additional 10 min at 37°C. The medium is then aspirated and the reaction stopped by the addition of 100 mM HCl or other methods. The plates are stored at 4°C for 15 min, and the cAMP content in the stopping solution is measured by radioimmunoassay. Radioactivity may be quantified using a gamma counter equipped with data reduction software. Specific modifications may be performed to optimize the assay for the GPCR or to alter the detection method of cAMP.

#### Arachidonic acid release assays

Cells expressing a GPCR and chimeric G protein are seeded into 96 well plates or other vessels and grown for 3 days in medium with supplements. <sup>3</sup>H-arachidonic acid (specific activity = 0.75 µCi/ml) is delivered as a 100 µL aliquot to each well and samples are incubated at 37° C, 5% CO<sub>2</sub> for 18 hours. The labeled cells are washed three times with medium. The wells are then filled with medium and the assay is initiated with the addition of test compounds or buffer in a total volume of 250 µL. Cells are incubated for 30 min at 37°C, 5% CO<sub>2</sub>. Supernatants are transferred to a microtiter plate and evaporated to dryness at 75°C in a vacuum oven. Samples are then dissolved and resuspended in 25 µL distilled water. Scintillant (300 µL) is added to each well

and samples are counted for  $^3\text{H}$  in a Trilux plate reader. Data are analyzed using nonlinear regression and statistical techniques available in the GraphPAD Prism package (San Diego, CA).

5

#### Intracellular calcium mobilization assay

Twenty four hours after transient transfection, COS-7 cells were seeded into 96-well black wall microtiter plates coated with poly-D-lysine for assay the following day. Just prior to assay, culture medium was aspirated and cells were dye-loaded with 4  $\mu\text{M}$  Fluo-3/ 0.01% pluronic acid in assay buffer composed of Hank's Balanced Salt Solution (138 mM NaCl, 5 mM KCl, 1.3 mM  $\text{CaCl}_2$ , 0.5 mM  $\text{MgCl}_2$ , 0.4 mM  $\text{MgSO}_4$ , 0.3 mM  $\text{KH}_2\text{PO}_4$ , 0.3 mM  $\text{Na}_2\text{HPO}_4$ , 5.6 mM glucose) plus 20 mM HEPES (pH 7.4), 0.1% BSA and 2.5 mM probenidol (100  $\mu\text{l}$ /well) for 1 hour in 5%  $\text{CO}_2$  at 37  $^\circ\text{C}$ . After excess dye was discarded, cells were washed in assay buffer and layered with a final volume equal to 100  $\mu\text{l}$ /well. Basal fluorescence was monitored in a fluorometric imaging plate reader (FLIPR<sup>TM</sup>, Molecular Devices) with an excitation wavelength of 488 nm and an emission range of 500 to 560 nm. Laser excitation energy was adjusted so that basal fluorescence readings were approximately 10,000 relative fluorescent units. Cells were stimulated with agonists diluted in assay buffer (50  $\mu\text{l}$ ), and relative fluorescent units were measured at defined intervals (exposure = 0.4 sec) over a 3 min period at room temperature. Maximum change in fluorescence was calculated for each well. Concentration-response curves derived from the maximum change in fluorescence were analyzed by nonlinear regression (Hill equation).

Alternatively, intracellular free calcium concentration may be measured by microspectrofluorimetry using the fluorescent indicator dye Fura-2/AM (Bush et al, 1991). Cells expressing the receptor and chimeric G protein are seeded onto a 35 mm culture dish containing a glass coverslip insert and allowed to adhere overnight. Cells are then washed with HBS and loaded with 100  $\mu$ L of Fura-2/AM (10  $\mu$ M) for 20 to 40 min. After washing with HBS to remove the Fura-2/AM solution, cells are equilibrated in HBS for 10 to 20 min. Cells are then visualized under the 40X objective of a Leitz Fluovert FS microscope and fluorescence emission is determined at 510 nm with excitation wavelengths alternating between 340 nm and 380 nm. Raw fluorescence data are converted to calcium concentrations using standard calcium concentration curves and software analysis techniques.

Alternative calcium-sensitive indicators may be used. Preferred examples of these are: aequorin, Fluo-3, Fluo-4, Fluo-5, Calcium Green-1, Oregon Green, and 488 BAPTA. After activation of the receptors with agonist ligands the emission elicited by the change of intracellular calcium concentration can be measured by a luminometer or a fluorescence imager; a preferred example of this is the fluorescence imager plate reader (FLIPR<sup>TM</sup>) as described above. Antagonist ligands are identified by the inhibition of the signal elicited by agonist ligands.

#### Inositol phosphate assay

Receptor mediated activation of the inositol phosphate (IP) second messenger pathways may be assessed by radiometric or other measurement of IP products. For example, in a 96 well microplate format

assay, cells are plated at a density of 70,000 cells per well and allowed to incubate for 24 hours. The cells are then labeled with 0.5  $\mu\text{Ci}$  [ $^3\text{H}$ ]myo-inositol overnight at 37°C, 5%  $\text{CO}_2$ . Immediately before the  
5 assay, the medium is removed and replaced with 90  $\mu\text{L}$  of PBS containing 10 mM LiCl. The plates are then incubated for 15 min at 37°C, 5%  $\text{CO}_2$ . Following the incubation, the cells are challenged with agonist (10  $\mu\text{L}$ /well; 10x concentration) for 30 min at 37°C, 5%  
10  $\text{CO}_2$ . The challenge is terminated by the addition of 100  $\mu\text{L}$  of 50% v/v trichloroacetic acid, followed by incubation at 4°C for greater than 30 minutes. Total IPs are isolated from the lysate by ion exchange chromatography. Briefly, the lysed contents of the  
15 wells are transferred to a Multiscreen HV filter plate (Millipore) containing Dowex AG1-X8 (200-400 mesh, formate form). The filter plates are prepared adding 100  $\mu\text{L}$  of Dowex AG1-X8 suspension (50% v/v, water: resin) to each well. The filter plates are  
20 placed on a vacuum manifold to wash or elute the resin bed. Each well is first washed 2 times with 200  $\mu\text{L}$  of 5 mM myo-inositol. Total [ $^3\text{H}$ ]inositol phosphates are eluted with 75  $\mu\text{L}$  of 1.2 M ammonium formate/0.1 M formic acid solution into 96-well  
25 plates. 200  $\mu\text{L}$  of scintillation cocktail is added to each well and the radioactivity is determined by liquid scintillation counting.

#### GTP $\gamma$ S binding assay

30 Membranes from cells expressing a GPCR and a chimeric G protein are suspended in assay buffer (e.g., 50 mM Tris, 100 mM NaCl, 5 mM  $\text{MgCl}_2$ , 10  $\mu\text{M}$  GDP, pH 7.4) with or without protease inhibitors (e.g., 0.1% bacitracin). Membranes are incubated on ice for 20  
35 minutes, transferred to a 96-well Millipore

microtiter GF/C filter plate and mixed with GTP $\gamma$ <sup>35</sup>S (e.g., 250,000 cpm/sample, specific activity ~1000 Ci/mmol) plus or minus unlabeled GTP $\gamma$ S (final concentration = 100  $\mu$ M). The final membrane protein concentration is approximately 20  $\mu$ g/ml. Samples are incubated in the presence or absence of test compounds for 30 minutes at room temperature, then filtered on a Millipore vacuum manifold and washed three times with cold (4<sup>0</sup>C) assay buffer. Samples collected in the filter plate are treated with scintillant and counted for <sup>35</sup>S in a Trilux (Wallac) liquid scintillation counter. It is expected that optimal results are obtained when the receptor membrane preparation is derived from an appropriately engineered heterologous expression system, i.e., an expression system resulting in high levels of expression of the receptor and/or expressing G proteins having high turnover rates (for the exchange of GDP for GTP). GTP $\gamma$ S assays are well-known to those skilled in the art, and it is contemplated that variations on the method described above, such as are described by Tian et al. (1994) or Lazareno and Birdsall (1993), may be used.

#### MAP kinase assay

MAP kinase (mitogen activated kinase) may be monitored to evaluate receptor activation. MAP kinase is activated by multiple pathways in the cell. A primary mode of activation involves the ras/raf/MEK/MAP kinase pathway. Growth factor (tyrosine kinase) receptors feed into this pathway via SHC/Grb-2/SOS/ras. Gi coupled receptors are also known to activate ras and subsequently produce an activation of MAP kinase. Receptors that activate phospholipase C (such as Gq /G11 -coupled) produce

diacylglycerol (DAG) as a consequence of phosphatidyl inositol hydrolysis. DAG activates protein kinase C which in turn phosphorylates MAP kinase.

5 MAP kinase activation can be detected by several approaches. One approach is based on an evaluation of the phosphorylation state, either unphosphorylated (inactive) or phosphorylated (active). The phosphorylated protein has a slower mobility in SDS-  
10 PAGE and can therefore be compared with the unstimulated protein using Western blotting. Alternatively, antibodies specific for the phosphorylated protein are available (New England Biolabs) which can be used to detect an increase in  
15 the phosphorylated kinase. In either method, cells are stimulated with the test compound and then extracted with Laemmli buffer. The soluble fraction is applied to an SDS-PAGE gel and proteins are transferred electrophoretically to nitrocellulose or  
20 Immobilon. Immunoreactive bands are detected by standard Western blotting technique. Visible or chemiluminescent signals are recorded on film and may be quantified by densitometry.

25 Another approach is based on evaluation of the MAP kinase activity via a phosphorylation assay. Cells are stimulated with the test compound and a soluble extract is prepared. The extract is incubated at 30°C for 10 min with gamma-<sup>32</sup>P-ATP, an ATP  
30 regenerating system, and a specific substrate for MAP kinase such as phosphorylated heat and acid stable protein regulated by insulin, or PHAS-I. The reaction is terminated by the addition of H<sub>3</sub>PO<sub>4</sub> and samples are transferred to ice. An aliquot is  
35 spotted onto Whatman P81 chromatography paper, which retains the phosphorylated protein. The

chromatography paper is washed and counted for  $^{32}\text{P}$  in a liquid scintillation counter. Alternatively, the cell extract is incubated with gamma- $^{32}\text{P}$ -ATP, an ATP regenerating system, and biotinylated myelin basic protein bound by streptavidin to a filter support. The myelin basic protein is a substrate for activated MAP kinase. The phosphorylation reaction is carried out for 10 min at  $30^\circ\text{C}$ . The extract can then be aspirated through the filter, which retains the phosphorylated myelin basic protein. The filter is washed and counted for  $^{32}\text{P}$  by liquid scintillation counting.

#### Cell proliferation assay

Receptor activation of a GPCR may lead to a mitogenic or proliferative response which can be monitored via  $^3\text{H}$ -thymidine uptake. When cultured cells are incubated with  $^3\text{H}$ -thymidine, the thymidine translocates into the nuclei where it is phosphorylated to thymidine triphosphate. The nucleotide triphosphate is then incorporated into the cellular DNA at a rate that is proportional to the rate of cell growth. Typically, cells are grown in culture for 1-3 days. Cells are forced into quiescence by the removal of serum for 24 hrs. A mitogenic agent is then added to the media. Twenty-four hrs later, the cells are incubated with  $^3\text{H}$ -thymidine at specific activities ranging from 1 to 10  $\mu\text{Ci/ml}$  for 2-6 hrs. Harvesting procedures may involve trypsinization and trapping of cells by filtration over GF/C filters with or without a prior incubation in TCA to extract soluble thymidine. The filters are processed with scintillant and counted for  $^3\text{H}$  by liquid scintillation counting. Alternatively, adherent cells are fixed in MeOH or TCA, washed in water, and solubilized in 0.05%

deoxycholate/0.1 N NaOH. The soluble extract is transferred to scintillation vials and counted for  $^3\text{H}$  by liquid scintillation counting.

5 Alternatively, cell proliferation can be assayed by measuring the expression of an endogenous or heterologous gene product, expressed by the cell line used to transfect the GPCR, which can be detected by methods such as, but not limited to, fluorescence  
10 intensity, enzymatic activity, immunoreactivity, DNA hybridization, polymerase chain reaction, etc.

#### Reporter gene assays

The chimeric  $\text{G}\alpha$  subunits described in this  
15 application can be used in conjunction with any number of  $\text{G}\alpha_q$ -linked transcriptional assays to include GPCRs that do not normally use  $\text{G}\alpha_q$  as their native signaling pathway. This application could include, but is not limited to, the use of  $\text{G}\alpha$   
20 chimeras to link activation of any GPCR to a fluorescent signal generated via a reporter enzyme such as  $\beta$ -lactamase placed under the transcriptional regulation of NFAT, SRE, CRE, AP-1, TRE IRE or other specific DNA regulatory elements or promoters  
25 (Naylor, 1999).

#### Methods for recording currents in *Xenopus* oocytes

Oocytes were harvested from *Xenopus laevis* and injected with mRNA transcripts as previously  
30 described (Quick and Lester, 1994; Smith et al., 1997). Receptor and chimeric G protein  $\alpha$  subunit RNA transcripts were synthesized using the T7 polymerase ("Message Machine," Ambion) from linearized plasmids or PCR products containing the complete coding region  
35 of the genes. Oocytes were injected with 5-25 ng

synthetic receptor RNA and incubated for 3-8 days at 17 degrees. Three to eight hours prior to recording, oocytes were injected with 500 pg chimeric G $\alpha$  subunit mRNA. Dual electrode voltage clamp (Axon Instruments Inc.) was performed using 3 M KCl-filled glass microelectrodes having resistances of 1-2 MOhm. Unless otherwise specified, oocytes were voltage clamped at a holding potential of -80 mV. During recordings, oocytes were bathed in continuously flowing (1-3 ml/min) medium containing 96 mM NaCl, 2 mM KCl, 1.8 mM CaCl<sub>2</sub>, 1 mM MgCl<sub>2</sub>, and 5 mM HEPES, pH 7.5 (ND96). Drugs were applied by local perfusion from a 10  $\mu$ l glass capillary tube fixed at a distance of 0.5 mm from the oocyte. Experiments were carried out at room temperature. All values are expressed as mean  $\pm$  standard error of the mean.

#### Beta-gamma-dependent signaling

Beta-gamma sub-units released from G $\alpha_q$  may interact with a variety of effectors, including phospholipase C beta, adenylate cyclase II and IV, ion channels (Kir 3.x family of K<sup>+</sup> channels, calcium channels), Ras and PI-3-gamma. Each of these may be monitored by specific read-outs known to those skilled in the art.

#### Expression cloning

The expression cloning strategy is a well-known method utilized to clone mammalian G protein-coupled receptors (Kluxen et al., 1992; Kiefer et al, 1992; Julius et al., 1988; US 5,545,549 and US 5,602,024, the disclosures of which are hereby incorporated by reference in their entireties into this application). A chimeric G protein of this invention may be utilized in expression cloning to facilitate identification of clones which encode mammalian G protein-coupled receptors. Cells, expressing the DNA

**THE** **NEW** **YORK** **PUBLIC** **LIBRARY**

## Results and Discussion

### Expression of *C. elegans* chimera in *Xenopus* oocytes

The chimeric  $G\alpha$  subunit consisting of  $cG\alpha_{q/z5}$ , wherein the C-terminal final 5 amino acids of  $cG\alpha_q$  are replaced with those of  $hG\alpha_z$  (Figure 2), was initially tested for expression and functional activity in *Xenopus* oocytes. Co-expression of  $cG\alpha_{q/z5}$  with the NPFF1 receptor resulted in the appearance of large amplitude  $Cl^-$  currents following application of 1  $\mu M$  NPFF ( $1258 \pm 159$  nA,  $n = 12$ ). The currents stimulated by NPFF in oocytes expressing NPFF1 and  $cG\alpha_{q/z5}$  were most likely mediated by the endogenous calcium-activated  $Cl^-$  channel (Gunderson et al., 1983), because they were blocked in oocytes injected with 50 nl of 10 mM EGTA (Figure 3). Chloride currents were also not observed from control oocytes expressing NPFF1 but lacking  $cG\alpha_{q/z5}$  ( $n=15$ ). In oocytes expressing NPFF1 and the human version of  $G\alpha_{q/z5}$ , response amplitudes ( $358 \pm 67$ ,  $n = 32$ ) were about one third of those in oocytes expressing the *C. elegans* version of this chimera. Similar results were obtained with four additional GPCRs, GALR1, Y1, NPFF2, and 5HT1D, that are known to couple to either  $G\alpha_i$  or  $G\alpha_o$  (Table 4; Watling, 1998). The increase in response was 2-3 fold over currents recorded from oocytes expressing the human version of the chimera. The exception to this trend was coupling to the Y5 receptor, which was actually reduced with  $cG\alpha_{q/z5}$ . Extending the length of the  $G\alpha_z$  portion of the C-terminal tail of  $cG\alpha_q$  to 9 amino acids ( $cG\alpha_{q/z9}$ ) did not further improve the amplitude of responses as compared to  $cG\alpha_{q/z5}$  (Table 4).

**TABLE 4.** Response amplitudes (nA) in oocytes expressing various GPCRs and chimeric G proteins. Values are mean  $\pm$  s.e.m (number of oocytes).

RECEPTOR	CHIMERA		
	hG $\alpha_{q/z5}$	cG $\alpha_{q/z5}$	cG $\alpha_{q/z9}$
<b>Rabbit 5HT1D</b>	90 $\pm$ 41 (14)	150 $\pm$ 105 (8)	34 $\pm$ 12 (9)
<b>Rat GALR1</b>	31 $\pm$ 16 (22)	91 $\pm$ 38 (15)	Not tested
<b>Human NPFF1</b>	358 $\pm$ 67 (32)	1258 $\pm$ 159 (12)	1449 $\pm$ 398 (5)
<b>Human NPFF2</b>	528 $\pm$ 99 (18)	1121 $\pm$ 261 (13)	Not tested
<b>Rat Y1</b>	841 $\pm$ 204 (19)	1549 $\pm$ 168 (13)	300 $\pm$ 177 (8)
<b>Rat Y5</b>	82 $\pm$ 43 (7)	0 $\pm$ 2 (8)	65 $\pm$ 34 (6)

5

#### Expression of chimeras in mammalian cells

To evaluate the utility of cG $\alpha_{q/z5}$  in mammalian cells, COS-7 cells were transiently transfected with either hG $\alpha_{q/z5}$  or cG $\alpha_{q/z5}$  plus a GPCR. In one example, cells transfected either with hG $\alpha_{q/z5}$  or cG $\alpha_{q/z5}$  plus the human D1 receptor, which is thought to be G $\alpha_s$ - and G $\alpha_{i/o}$ -coupling (Sidhu et al., 1991), were stimulated with dopamine at concentrations up to 100  $\mu$ M and monitored for calcium mobilization (Figure 4). Whereas an agonist-induced response was undetectable with hG $\alpha_{q/z5}$  (n = 2), the cG $\alpha_{q/z5}$  construct supported an average maximum dopamine-stimulated signal of 12,120 relative fluorescence units (n = 2).

The data for human D1 clearly demonstrate that the probability of GPCR signal detection in mammalian cells can be enhanced by the use of a chimeric construct containing an invertebrate  $G\alpha_q$  backbone (*C. elegans*  $G\alpha_q$  in this case). To determine whether this effect extends to a broad range of GPCRs, c $G\alpha_{q/z5}$  was co-transfected into COS-7 cells with a panel of 36 different GPCRs, including  $G\alpha_{i/o}$ -,  $G\alpha_s$ -, and  $G\alpha_q$ -coupling receptors. Seventy eight percent (28/36) of the receptors generated positive signals (defined as > 500 fluorescence units) with c $G\alpha_{q/z5}$ , compared to only 58% with h $G\alpha_{q/z5}$  (Table 5). Extending the  $G\alpha_z$  tail length from 5 to 9 amino acids did not significantly change the detection rate (29/36 positive responses > 500 fluorescence units) but there was a trend, particularly among the most responsive receptors, toward a decreased maximal response. From these data, we can conclude that an invertebrate-based  $G\alpha_{q/z}$  construct is optimal for detecting a broad range of GPCR, and we can identify c $G\alpha_{q/z5}$  as a preferred design.

**TABLE 5.**  $G\alpha_{q/z5}$  chimeras and GPCR in COS-7 cells: agonist-induced response. Transfected cells were monitored for calcium mobilization in the FLIPR™ using the calcium sensitive dye Fluo-3. Maximum agonist concentrations were 100  $\mu$ M for non-peptide ligands or 10  $\mu$ M for peptide ligands, except for neurotensin (1  $\mu$ M). Fluorescence data represent the mean from 2 or more experiments. h = human; m = mouse; r = rat; adr = adrenergic; DA = dopamine; GLP-1 = glucagon-like peptide; 5HT = serotonin; GAL = galanin; NE = norepinephrine; MCH = melanin-concentrating hormone; NPY = neuropeptide Y; PP =

pancreatic polypeptide; NPFF = neuropeptide FF; and NT = neurotensin

#	RECEPTOR	PROPOSED COUPLING	AGONIST	MAXIMAL SIGNAL (FLUORESCENCE UNITS)		
				hG $\alpha_q/z5$	cG $\alpha_q/z5$	cG $\alpha_q/z9$
1	h D3	G $\alpha_{i/o}$	DA	0	0	121
2	h GLP-1	G $\alpha_s$	GLP-1	287	131	135
3	h 5HT7	G $\alpha_s$	5HT	90	166	129
4	h 5HT1E	G $\alpha_{i/o}$	5HT	202	229	238
5	h 5HT1F	G $\alpha_{i/o}$	5HT	0	243	384
6	m 5HT5B	G $\alpha_{i/o}$	5HT	251	265	443
7	m 5HT5A	G $\alpha_{i/o}$	5HT	0	351	270
8	h 5HT1D	G $\alpha_{i/o}$	5HT	316	414	504
9	h D5	G $\alpha_s$ , G $\alpha_{i/o}$	DA	782	657	797
10	h 5HT1B	G $\alpha_{i/o}$	5HT	405	929	1217
11	h 5HT4	G $\alpha_s$ , G $\alpha_q$	5HT	2161	1011	1696
12	h 5HT6	G $\alpha_s$	5HT	210	1289	2287
13	h GALR3	G $\alpha_{i/o}$	GAL	804	1523	2050
14	h $\beta_2$ adr	G $\alpha_s$ , G $\alpha_{i/o}$	NE	128	1842	1697
15	h 5HT1A	G $\alpha_{i/o}$	5HT	478	1997	3139
16	r GALR3	G $\alpha_{i/o}$	GAL	2796	2298	2971
17	h MCH	G $\alpha_q$	MCH	783	2699	3332
18	r GALR1	G $\alpha_{i/o}$	GAL	82	3086	5947
19	r Y4	G $\alpha_{i/o}$	PP	4388	3662	2583
20	h $\alpha_2C$ adr	G $\alpha_{i/o}$	NE	6106	4143	3874
21	r GALR2	G $\alpha_q$	GAL	4862	4198	4470
22	h $\alpha_2B$ adr	G $\alpha_{i/o}$	NE	4515	4983	5138
23	h Y5	G $\alpha_{i/o}$	NPY	6407	5314	6680
24	h GALR2	G $\alpha_q$	GAL	5992	5470	4899
25	h kappa	G $\alpha_{i/o}$	U-69593	7864	5975	3472

#	RECEPTOR	PROPOSED COUPLING	AGONIST	MAXIMAL SIGNAL (FLUORESCENCE UNITS)		
				hGα <sub>q/z5</sub>	cGα <sub>q/z5</sub>	cGα <sub>q/z9</sub>
26	h NPFF1	Gα <sub>i/o</sub>	NPFF	4717	6593	2966
27	h NPFF2	Gα <sub>i/o</sub>	NPFF	19960	7566	4578
28	h α2A adr	Gα <sub>i/o</sub>	NE	10933	7575	3040
29	h D2	Gα <sub>i/o</sub>	DA	15579	7615	4305
30	h GALR1	Gα <sub>i/o</sub>	GAL	4061	7648	8489
31	h Y2	Gα <sub>i/o</sub>	NPY	10908	7708	5387
32	h Y1	Gα <sub>i/o</sub>	NPY	1879	7722	6728
33	h Y4	Gα <sub>i/o</sub>	PP	9966	9422	7397
34	h α1A adr	Gα <sub>q</sub>	NE	14167	9816	6597
35	h D1	Gα <sub>s</sub> , Gα <sub>i/o</sub>	DA	0	12120	13099
36	r NTR1	Gα <sub>q</sub>	NT	11171	14476	6111

#### Gα<sub>q/s</sub> Chimeras

To identify additional uses for an invertebrate-based Gα<sub>q</sub> construct, modifications were made to the backbone and C-terminus of another type of chimera, Gα<sub>q/s</sub>. Initially, the function of hGα<sub>q/s5</sub> was compared with that of hGα<sub>q/s9</sub>. In one example, either construct was co-transfected into COS-7 cells with the human D1 receptor, which is typically Gα<sub>s</sub>- or Gα<sub>i/o</sub>-coupling (Sidhu et al., 1991). Transfected cells were stimulated with dopamine at concentrations up to 100 μM and monitored for calcium mobilization. The average maximal agonist-induced response ranged from undetectable with hGα<sub>q/s5</sub> (n = 2) to 5692 relative fluorescent units with hGα<sub>q/s9</sub> (n = 4). The positive effect of increasing the Gα<sub>s</sub> tail length contrasts with data for *C. elegans* Gα<sub>q/z</sub>-type chimeras and has not been described previously (Conklin et

al., 1993, 1996). To further enhance signal detection, the human  $G\alpha_q$  backbone was replaced with the corresponding sequence from *C. elegans*  $G\alpha_q$ . The modified construct,  $cG\alpha_{q/s9}$ , was co-transfected into COS-7 cells together with the human D1 receptor, and transfected cells were stimulated with dopamine at concentrations up to 100  $\mu$ M. The average maximal dopamine-stimulated fluorescent signal with  $cG\alpha_{q/s9}$  was 8692 fluorescent units ( $n = 4$ ), a 1.5-fold increase over the response with  $hG\alpha_{q/s9}$ . To test the general utility of  $cG\alpha_{q/s9}$  for detection of  $G\alpha_s$ -coupling receptors, this construct was co-transfected into COS-7 with a panel of 7 such GPCR. When cells were stimulated with appropriate agonists, 6/7 = 81% of the  $G\alpha_s$ -coupling receptors generated positive responses ( $> 500$  fluorescence units). Further extension of the C-terminal  $G\alpha_s$  tail to 21 amino acids ( $cG\alpha_{q/s21}$ ) yielded similar results overall, both in terms of detection rate and maximal response (Table 6).

**TABLE 6.**  $G\alpha_{q/s}$  chimeras and  $G_s$ -coupled receptors in COS-7 cells: maximum agonist response. Transfected cells were monitored for calcium mobilization in the FLIPR<sup>TM</sup> using the calcium sensitive dye Fluo-3. Maximal agonist concentration was 100  $\mu$ M for non-peptide ligands or 10  $\mu$ M for GLP-1 (7-36) amide. Fluorescence data represent the mean from 2 or more experiments. h = human, adr = adrenergic, DA = dopamine; GLP-1 = glucagon-like peptide; 5HT = serotonin; NE = norepinephrine

#	RECEPTOR	AGONIST	MAXIMAL SIGNAL (FLUORESCENCE UNITS)			
			hGα <sub>q/s5</sub>	HGα <sub>q/s9</sub>	cGα <sub>q/s9</sub>	cGα <sub>q/s21</sub>
1	h GLP-1	GLP-1	189	4198	2461	3120
2	h 5HT7	5HT	0	0	387	206
3	h D5	DA	0	745	1870	3385
4	h 5HT4	5HT	1709	2309	1701	1731
5	h 5HT6	5HT	98	999	1639	1009
6	h β2 adr	NE	43	1439	3106	3513
7	h D1	DA	0	5692	8692	9433

That the *C. elegans* backbone provides a signaling advantage when incorporated into either Gα<sub>q/z</sub>-type or Gα<sub>q/s</sub>-type chimeras suggests a novel and general method for designing effective chimeric constructs. In yet another example, human Gα<sub>q/i3(5)</sub> was compared with *C. elegans* Gα<sub>q/i3(5)</sub> using COS-7 cells transfected with the rat GALR3 receptor. The maximum signal produced by porcine galanin was 2084 relative fluorescent units with human Gα<sub>q/i3(5)</sub> (n = 4), compared to 2564 fluorescent units with *C. elegans* Gα<sub>q/i3(5)</sub> (n = 4). These data extend the range of possible uses for a *C. elegans* backbone in a Gα<sub>q</sub> chimeric construct.

#### Multiple chimerae strategies

Application of this technology to a high throughput screening paradigm (such as orphan receptor screening or expression cloning) requires that a maximal number of chimera-dependent receptors (Gα<sub>i/o</sub> and Gα<sub>s</sub>-coupling) can function under the same conditions as chimera-independent receptors (Gα<sub>q</sub>-coupled). One strategy, described above, is to use a single extremely promiscuous construct such as cGα<sub>q/z5</sub>.

Another strategy is to combine multiple chimeras in a transfection mixture. Ideally, the mixture should be reduced to its essential components, both in terms of individual chimera and corresponding cDNA or mRNA. A reductionist approach has several advantages: 1) it increases the allowance for cDNA or mRNA encoding the GPCR of interest; 2) it reduces potential competition for protein translation; and 3) it reduces the risk for dominant negative suppression of Gq-coupled receptor function. A simple and effective combination could be formed with a  $cG\alpha_{q/z}$ -type chimera and a  $cG\alpha_{q/s}$ -type chimera. In one example, a transfection mixture containing 2  $\mu$ g  $cG\alpha_{q/z9}$  cDNA, 2  $\mu$ g  $cG\alpha_{q/s9}$  cDNA, and 16  $\mu$ g GPCR cDNA was transfected into COS-7 cells for subsequent monitoring of calcium mobilization. Out of 36 receptors tested, 28 receptors = 78% were detectable upon agonist stimulation with maximal signals > 500 fluorescence units (Table 7). The detection rate was identical to that obtained previously with  $cG\alpha_{q/z5}$  or  $cG\alpha_{q/z9}$  alone, except that the two chimerae together favored detection of the  $G\alpha_s$ -coupling receptor, human GLP-1. The use of multiple chimerae therefore represents an alternative method for screening various receptor types ( $G\alpha_{i/Go}$ -,  $G\alpha_s$ , and  $G\alpha_q$ -coupled) in a single assay format.

**TABLE 7.** Chimerae  $cG\alpha_{q/z9}$  and  $cG\alpha_{q/s9}$  and GPCRs in COS-7 cells: agonist-induced responses. Two  $\mu$ g  $cG\alpha_{q/z9}$ , 2  $\mu$ g  $cG\alpha_{q/s9}$ , and 16  $\mu$ g GPCR cDNA were transfected into COS-7 cells. Transfected cells were monitored for calcium mobilization in the FLIPR<sup>TM</sup> using the calcium sensitive dye Fluo-3. Maximum agonist concentrations were 100  $\mu$ M for non-peptide ligands or 10  $\mu$ M for peptide ligands, except for neurotensin (1  $\mu$ M).

Fluorescence data represent the mean from 2 or more experiments. h = human; m = mouse; r = rat; adr = adrenergic; DA = dopamine; GLP-1 = glucagon-like peptide; 5HT = serotonin; GAL = galanin; NE = norepinephrine; MCH = melanin-concentrating hormone; NPY = neuropeptide Y; PP = pancreatic polypeptide; NPFF = neuropeptide FF; and NT = neurotensin

#	RECEPTOR	PROPOSED COUPLING	AGONIST	MAXIMAL SIGNAL (FLUORESCENCE UNITS)
				$CG\alpha_{q/z9} + CG\alpha_{q/s9}$
1	h D3	$G\alpha_{i/o}$	DA	208
2	h GLP-1	$G\alpha_s$	GLP-1	794
3	h 5HT7	$G\alpha_s$	5HT	292
4	h 5HT1E	$G\alpha_{i/o}$	5HT	2
5	h 5HT1F	$G\alpha_{i/o}$	5HT	247
6	m 5HT5B	$G\alpha_{i/o}$	5HT	0
7	m 5HT5A	$G\alpha_{i/o}$	5HT	45
8	h 5HT1D	$G\alpha_{i/o}$	5HT	433
9	h D5	$G\alpha_s, G\alpha_{i/o}$	DA	1172
10	h 5HT1B	$G\alpha_{i/o}$	5HT	190
11	h 5HT4	$G\alpha_s, G\alpha_q$	5HT	2345
12	h 5HT6	$G\alpha_s$	5HT	1598
13	h GALR3	$G\alpha_{i/o}$	GAL	853
14	h $\beta_2$ adr	$G\alpha_s, G\alpha_{i/o}$	NE	2346
15	h 5HT1A	$G\alpha_{i/o}$	5HT	2161
16	r GALR3	$G\alpha_{i/o}$	GAL	1402
17	h MCH	$G\alpha_q$	MCH	4808
18	r GALR1	$G\alpha_{i/o}$	GAL	1544
19	r Y4	$G\alpha_{i/o}$	PP	1015
20	h $\alpha_2C$ adr	$G\alpha_{i/o}$	NE	2341

#	RECEPTOR	PROPOSED COUPLING	AGONIST	MAXIMAL SIGNAL (FLUORESCENCE UNITS)
				$CG\alpha_{q/29} + CG\alpha_{q/s9}$
21	r GALR2	$G\alpha_q$	GAL	2665
22	h $\alpha 2B$ adr	$G\alpha_{i/o}$	NE	4855
23	h Y5	$G\alpha_{i/o}$	NPY	982
24	h GALR2	$G\alpha_q$	GAL	4630
25	h kappa	$G\alpha_{i/o}$	U-69593	3529
26	h NPFF1	$G\alpha_{i/o}$	NPFF	793
27	h NPFF2	$G\alpha_{i/o}$	NPFF	1582
28	h $\alpha 2A$ adr	$G\alpha_{i/o}$	NE	5284
29	h D2	$G\alpha_{i/o}$	DA	5549
30	h GALR1	$G\alpha_{i/o}$	GAL	8097
31	h Y2	$G\alpha_{i/o}$	NPY	3329
32	h Y1	$G\alpha_{i/o}$	NPY	2333
33	h Y4	$G\alpha_{i/o}$	PP	4133
34	h $\alpha 1A$ adr	$G\alpha_q$	NE	7585
35	h D1	$G\alpha_s, G\alpha_{i/o}$	DA	13516
36	r NTR1	$G\alpha_q$	NT	4264

#### Summary of the results

5 This work describes a functional assay with which various types and large numbers of GPCRs can be detected. The method is based on the premise that  $G\alpha$  proteins are derived from a common ancestor, and that the further a  $G\alpha$  protein is evolutionarily from the ancestral sequence, the more likely it is to contain motifs which restrict interactions to a subset of GPCRs. Conversely, sequences from more primitive organisms such as invertebrates may lack the restrictive motifs. Focusing specifically on  $G\alpha_q$ , we

10

performed an amino acid sequence alignment of all known protein structures and identified distinct motifs, which differentiate vertebrate from invertebrate species (Figure 5). For example, invertebrates lack the 6 amino acid N-terminal extension proposed to restrict GPCR interaction (Kostenis et al., 1998), and also contain Glu<sup>18</sup>-Lys<sup>19</sup> instead of the vertebrate Ala<sup>18</sup>-Arg<sup>19</sup> in a region of G $\alpha_q$  associated with receptor recognition (Lambright et al., 1996). These structural differences led us to speculate that an invertebrate G $\alpha_q$  backbone might function differently in a G $\alpha_q$  chimeric construct than would a vertebrate homologue, and that this difference might be expressed as an increase in GPCR/chimera promiscuity.

This hypothesis was tested using the invertebrate *C. elegans* as the source of the G $\alpha_q$  backbone, combined with C-terminal mammalian G $\alpha$  tails 5, 9 or 21 amino acids in length. cG $\alpha_{q/25}$  was more promiscuous than any previously described G $\alpha$  construct, supporting receptor activation when co-transfected into *Xenopus* oocytes or mammalian COS-7 cells with most G $\alpha_{i/o}$ -, G $\alpha_s$ , and G $\alpha_q$ -coupling receptors. This result was unexpected, and contrasts with the prevailing expectations of experts in the field (Milligan and Rees, 1999). Indeed, the current data (Conklin et al., 1993, 1996; Milligan and Rees, 1999) support the idea that each G protein chimera is only capable of functional interaction with a limited range of receptors. If true, this perceived limitation would necessitate the assay of each GPCR against a panel of chimeric G proteins in order to identify an effective GPCR/G protein combination. The results indicate that certain chimeras, such as cG $\alpha_{q/25}$ , are able to

effectively couple to a very wide number of GPCRs, thus eliminating the need for such multiple assays.

*C. elegans*  $G\alpha_{q/z5}$  may be used alone or combined with a second chimera such as  $cG\alpha_{q/s9}$  to further increase the detection rate especially for  $G\alpha_s$ -coupled receptors.

Conserved motifs within invertebrate  $G\alpha_q$  subunits predict enhanced promiscuity from the use of any invertebrate  $G\alpha_q$  backbone, including, but not limited to, the known  $G\alpha_q$  sequences listed in Table 8. To provide experimental evidence for this we cloned and expressed a *D. melanogaster* chimera ( $dG\alpha_{q/z5}$ ; Figure 2) containing the five C-terminal amino acids of human  $G\alpha_z$ . A comparison of  $cG\alpha_{q/z5}$ ,  $dG\alpha_{q/z5}$  and  $hG\alpha_{q/z5}$  revealed that the two invertebrate chimeras show a similar enhanced coupling to D1 receptors as compared to the corresponding human chimera (Table 9). These data strongly argue against the possibility that *C. elegans*  $G\alpha_q$  is somehow unique in its ability to couple promiscuously. Rather, the *D. melanogaster* data suggest that many, if not all, invertebrate  $G\alpha_q$  genes may provide a similarly enhanced utility to couple to a wide variety of GPCRs.

The general utility of employing  $G\alpha$  subunits from primitive organisms may be extended to include non- $G\alpha_q$  subunits from organisms outside of the animal kingdom, including for example, members of the genus *Dictyostelium*. The G-protein  $\alpha$  subunits of *Dictyostelium discoideum* do not readily fall into those classes defined for members of the animal kingdom (Wilkie and Yokoyama, 1994), however, individual  $G\alpha$  subunits such as G alpha 2 have been

shown to directly activate the PLC pathway (Okaichi et al., 1992). Other  $G\alpha$  subunits of *Dictyostelium*, such as  $G\alpha_4$ , may also be useful based on their homology to member of the  $G\alpha_q$  family. For example,  $G\alpha_4$  exhibits a greater homology to *C. elegans*  $G\alpha_q$  than does  $G\alpha_2$  (47% vs. 42% at the amino acid level). Therefore, it is anticipated that  $G\alpha$  subunits from *Dictyostelium*, with or without amino acid substitutions within the protein, may be useful for functional assays for GPCRs. Therefore, for the purposes of this invention, the term invertebrate  $G\alpha_q$  G protein includes *Dictyostelium*  $G\alpha_2$  ( $G\alpha_2$ ) and  $G\alpha_4$  ( $G\alpha_4$ ) G proteins.

Further enhancements to the coupling scope of the chimeric G proteins described in this invention may be realized by making select point mutations within regions of the protein known to contact GPCRs. For example, amino acids within the  $\alpha_4$  helical domain of  $G\alpha_{11}$  are important for permitting a productive coupling to the 5HT1B receptor (Bae et al., 1999). Mutations altering two amino acids in this domain, Q304 and E308, specifically prevent coupling to 5HT1B. The majority of receptors that did not couple productively to the chimeric G proteins described herein include several members of the 5HT1 subfamily, including 5HT1B. It is predicted, therefore, based on the work of Bae et al. (1999) that making homologous amino acid substitutions in the  $\alpha_4$  region of  $cG\alpha_q$  would extend the number of GPCRs that can functionally couple to chimeras, composed of  $cG\alpha_q$ .

**TABLE 8.** Description of  $G\alpha_q$  subunits from invertebrates useful for construction of chimeras.

<b>SPECIES</b>	<b>COMMON NAME</b>	<b>DESIGNATION</b>	<b>GENBANK ACCESSION NUMBER</b>
<i>Drosophila melanogaster</i>	Fruit fly	GBQ1_drome	P23625
<i>Drosophila melanogaster</i>	Fruit fly	GBQ3_drome	P54400
<i>Limulus polyphemus</i>	Horseshoe crab	GBQ_limpo	g1857923
<i>Patinopecten yessoensis</i>	Scallop	GBQ_patye	O15975
<i>Loligo forbesi</i>	Squid	GBQ_lolfo	P38412
<i>Homarus americanus</i>	Lobster	GBQ_homam	P91950
<i>Lymnaea stagnalis</i>	Pond snail	GBQ_lymst	P38411
<i>Geodia cydonium</i>	Sponge	GBQ_geocy	Y14248
<i>Caenorhabditis elegans</i>	Nematode	GBQ_caeel	AF003739

**TABLE 9.** Comparison of invertebrate chimerae dG $\alpha_{q/z5}$  and cG $\alpha_{q/z5}$  with two different human hG $\alpha_{q/z5}$  chimerae in their ability to couple to human D1 receptors in COS-7 cells. Ten  $\mu$ g chimera cDNA and 10  $\mu$ g of human D1 receptor cDNA were transfected into COS-7 cells. Transfected cells were monitored for calcium mobilization in the FLIPR™ using the calcium sensitive dye Fluo-3. Maximum agonist concentration was 100  $\mu$ M dopamine. Fluorescent data represent the mean from two experiments.

MAXIMAL SIGNAL (FLUORESCENCE UNITS)			
dG $\alpha_{q/z5}$	cG $\alpha_{q/z5}$	hG $\alpha_{q/z5}$ *	hG $\alpha_{q/z5}$ †
2149	4832	0	0

\* Identical to Accession number L76256.

† Ala  $\rightarrow$  Ser substitution at position 171.

This invention provides a powerful and rapid system for detecting GPCR activation that is obtained when an invertebrate-based G $\alpha_q$  chimera is coupled to a signal amenable to high throughput screening, such as fluorescence-based detection of calcium mobilization. Specific applications would include: 1) high throughput screening and pharmacological analysis of a known GPCR, e.g., drug discovery; 2) screening of ligands against a cloned orphan receptor whose signaling pathways are unknown; and 3) screening of a cDNA library against one or more ligands in an expression cloning paradigm. In each case, this method supports detection of GPCRs from various classes (G $\alpha_{i/o}$ , G $\alpha_s$ -, and G $\alpha_q$ -coupling) in a single assay format with greater efficiency and capture rate than previously described methods.

**REFERENCES**

- 5 Bae, H., Cabrera-Vera, T.M., Depree, K.M., et al.  
 "Two amino acids within the alpha4 helix of Galphail  
 mediate coupling with 5-hydroxytryptamine1B  
 receptors" *J. Biol. Chem.* 274: 14963-14971 (1999).
- 10 Barnes, R.D. "Invertebrate Zoology" W.B. Saunders  
 Company, Philadelphia, p. 1 (1974).
- Bourne, H.R. "How receptors talk to trimeric G  
 proteins" *Curr.Opin.Cell Biol.* 9: 134-142 (1997).
- 15 Bradford, M.M. "A rapid and sensitive method for the  
 quantitation of microgram quantities of protein  
 utilizing the principle of protein-dye binding" *Anal.*  
*Biochem.* 72: 248-254 (1976).
- 20 Burgevin, M.-C., Loquet, I., Quarteronet, D., Habert-  
 Ortolí, E. "Cloning, pharmacological  
 characterization, and anatomical distribution of a  
 rat cDNA encoding for a galanin receptor" *J. Molec.*  
*Neurosci.* 6: 33-41 (1995).
- Bush, A.B., et al. "Nerve growth factor potentiates  
 bradykinin-induced calcium influx and release in PC12  
 cells" *J. Neurochem.* 57: 562-574 (1991).
- 25 The *C. elegans* Sequencing Consortium. "Genome  
 sequence of the nematode *C. elegans*: a platform for  
 investigating biology" *Science* 282: 2012-2018 (1998).
- 30 Conklin, B.R., et al. "Substitution of three amino  
 acids switches receptor specificity of Gq alpha to  
 that of Gi alpha" *Nature* 363: 274-276 (1993).
- Conklin, B.R., Herzmark, P., Ishida, S., et al.  
 "Carboxyl-terminal mutations of Gq alpha and Gs alpha

that alter the fidelity of receptor activation" *Mol. Pharmacol.* 50: 885-890 (1996).

5 Cullen, B.R. "Use of eukaryotic expression technology in the functional analysis of cloned genes" *Methods Enzymol.* 152:684-704 (1987).

Dascal, N., et al. "Atrial G protein-activated K<sup>+</sup> channel: expression cloning and molecular properties" *Proc. Natl. Acad. Sci. USA* 90:10235-10239 (1993).

10 Dillon, J.S., Tanizawa, Y., Wheeler, M.B., et al. "Cloning and functional expression of the human glucagon-like peptide-1 (GLP-1) receptor" *Endocrinology* 133: 1907-1910 (1993).

15 Dixon, R.A., Kobilka, B.K., Strader, D.J., et al. "Cloning of the gene and cDNA for mammalian beta-adrenergic receptor and homology with rhodopsin" *Nature* 321: 75-79 (1986).

20 Eva, C., Keinanen, K., Monyer, H., Seeburg, P., Sprengel, R. "Molecular cloning of a novel G protein-coupled receptor that may belong to the neuropeptide receptor family" 271: 80-84 (1990).

Gundersen, C.B., et al. "Serotonin receptors induced by exogenous messenger RNA in *Xenopus* oocytes" *Proc. R. Soc. Lond. B. Biol. Sci.* 219(1214): 103-109 (1983).

25 Habert-Ortoli, E., Amiranoff, B., Loquet, I., Laburthe, M., and Mayaux, J.-F. "Molecular cloning of a functional human galanin receptor" *Proc. Natl. Acad. Sci. USA* 91: 9780-9783 (1994).

30 Harwood, G., Lockyer, M., Giles, H., Fairweather, N. "Cloning and characterisation of the rabbit 5-HT1D

alpha and 5-HT1D beta receptors" *FEBS Lett.* 377:  
73-76 (1995).

5 Inanobe, A., et al. "Characterization of G protein-  
gated  $K^+$  channels composed of Kir3.2 subunits in  
dopaminergic neurons of the substantia nigra" *J.*  
*Neurosci.* 19:1006-1017 (1999).

10 Jansen, G., Thijssen, K.L., Werner, P., van der  
Horst, M., Hazendonk, E. & Plasterk, R.H. "The  
complete family of genes encoding G proteins of  
Caenorhabditis elegans" *Nat. Genet.* 21: 414-419  
(1999).

15 Julius, D., MacDermott, A.B., Axel, R., Jessell, T.M.  
"Molecular characterization of a functional cDNA  
encoding the serotonin 1c receptor" *Science* 241:  
558-564 (1988).

Keeton, W.T. "Biological Science" W.W. Norton & Co.,  
New York, p. 1017 (1980).

20 Kieffer, B., Befort, K., Gaveriaux-Ruff, C., Hirth,  
C.G. "The  $\delta$ -opioid receptor: Isolation of a cDNA by  
expression cloning and pharmacological  
characterization" *Proc. Natl. Acad. Sci. USA* 89:  
12048-12052 (1992).

25 Kluxen, F.W., Bruns, C., Lubbert, H. "Expression  
cloning of a rat brain somatostatin receptor cDNA"  
*Proc. Natl. Acad. Sci. USA* 89: 4618-4622 (1992).

30 Kobilka, B.K., Frielle, T., Collins, S., et al. "An  
intronless gene encoding a potential member of the  
family of receptors coupled to guanine nucleotide  
regulatory proteins" *Nature* 329: 75-79 (1987).

- Kohen, R., Metcalf, M.A., Khan, N., Druck, T., Huebner, K., Lachowicz, J.E., Meltzer, H.Y., Sibley, D.R., Roth, B.L., Hamblin, M.W. "Cloning, characterization, and chromosomal localization of a human 5-HT<sub>6</sub> serotonin receptor" *J. Neurochem.* 66: 47-56 (1996).
- Kostenis, E., Degtyarev, M. Y., Conklin, B. R., Wess, J. "The N-terminal extension of Galphaq is critical for constraining the selectivity of receptor coupling" *J. Biol. Chem.* 272: 19107-19110 (1997).
- Kostenis, E., Zeng, F.Y., Wess, J. "Functional characterization of a series of mutant G protein alphaq subunits displaying promiscuous receptor coupling properties" *J Biol. Chem.* 273: 17886-17892 (1998).
- Krapivinsky, G., et al. "The cardiac inward rectifier K<sup>+</sup> channel subunit, CIR, does not comprise the ATP-sensitive K<sup>+</sup> channel, IKATP" *J. Biol. Chem.* 270:28777-28779 (1995b).
- Krapivinsky, G., et al., "The G protein-gated atrial K<sup>+</sup> channel IKACH is a heteromultimer of two inwardly rectifying K(+) -channel proteins" *Nature* 374:135-141 (1995).
- Kubo, Y., et al. "Primary structure and functional expression of a rat G protein-coupled muscarinic potassium channel" *Nature* 364:802-806 (1993).
- Lambright, D.G., Sondek, J., Bohm, A., Skiba, N.P., Hamm, H.E. & Sigler, P.B. "The 2.0 A crystal structure of a heterotrimeric G protein" *Nature* 379: 311-319 (1996).

Larhammar, D., Blomqvist, A.G., Yee, F., Jazin, E.,  
Yoo, H., Wahlestedt, C.R. "Cloning and functional  
expression of a human neuropeptide Y/peptide YY  
receptor of the Y1 type" *J. Biol. Chem.* 267: 10935-  
5 10938 (1992).

Lazareno, S. and Birdsall, N.J.M. "Pharmacological  
characterization of acetylcholine stimulated [35S]-  
GTPyS binding mediated by human muscarinic m1-m4  
receptors: antagonist studies" *Br. J. Pharmacol.* 109:  
10 1120-1127 (1993).

Mansson, E., Bare, L., Yang, D. "Isolation of a human  
kappa opioid receptor cDNA from placenta" *Biochem  
Biophys Res Commun.* 202: 1431-1437 (1994).

Matthes, H., Boschert, U., Amlaiky, N., Grailhe, R.,  
15 Plassat, J.L., Muscatelli, F., Mattei, M.G., Hen, R.  
"Mouse 5-hydroxytryptamine<sub>5A</sub> and 5-  
hydroxytryptamine<sub>5B</sub> receptors define a new family of  
serotonin receptors: cloning, functional expression,  
and chromosomal localization" *Mol. Pharmacol.* 43:  
20 313-319 (1993).

Milligan, G. and Rees, S. "Chimeric G $\alpha$  proteins:  
their potential use in drug discovery" *Trends  
Pharmacol. Sci.* 20: 118-124 (1999).

25 Naylor, L.H. "Reporter gene technology: the future  
looks bright" *Biochem. Pharmacol.* 58(5): 749-757  
(1999).

Offermans, S. and Simon, M.I. "G $\alpha_{15}$  and G $\alpha_{16}$  couple a  
wide variety of receptors to phospholipase C" *J.  
30 Biol. Chem.* 270: 15175-15180 (1995).

- Okaichi, K., Cubitt, A.B., Pitt, G.S. and Firtel, R.A. "Amino acid substitutions in the Dictyostelium G alpha subunit G alpha 2 produce dominant negative phenotypes and inhibit the activation of adenylyl cyclase, guanylyl cyclase, and phospholipase C" *Mol Biol Cell* 3: 735-747 (1992).
- Plassat, J.L., Boschert, U., Amlaiky, N., Hen, R. "The mouse 5HT5 receptor reveals a remarkable heterogeneity within the 5HT1D receptor family" *EMBO J.* 11: 4779-4786 (1992).
- Quick, M.W. and Lester, H.A. "Methods for expression of excitability proteins in *Xenopus* oocytes" *Meth. Neurosci.* 19: 261-279 (1994).
- Salon, J.A. and Owicki, J.A., "Real-time measurements of receptor activity: Application of microphysiometric techniques to receptor biology" *Methods in Neuroscience* 25: pp. 201-224, Academic Press (1996).
- Seack, J., Kruse, M. & Muller, W.E. "Evolutionary analysis of G proteins in early metazoans: cloning of alpha- and beta-subunits from the sponge *Geodia cydonium*." *Biochim.Biophys Acta*", 1401: 93-103 (1998).
- Sidhu, A. et al. "D1 dopamine receptors can interact with both stimulatory and inhibitory guanine nucleotide binding proteins" *J. Neurochem.* 57: 1445-1451 (1991).
- Simon, M.I., Strathmann, M.P., Gautam, N. "Diversity of G proteins in signal transduction" *Science* 252: 802-808 (1991).

Smith, K.E., et al. "Expression cloning of a rat hypothalamic galanin receptor coupled to phosphoinositide turnover" *J. Biol. Chem.* 272: 24612-24616 (1997).

- 5 Suga, H., Koyanagi, M., Hoshiyama, D., Ono, K., Iwabe, N., Kuma, K., Miyata, T. "Extensive gene duplication in the early evolution of animals before the parazoan-eumetazoan split demonstrated by G proteins and protein tyrosine kinases from sponge and  
10 hydra" *J. Mol. Evol.* 48: 646-653 (1999).

Sunahara, R.K., Dessauer, C.W., and Gilman, A.G. "Complexity and diversity of mammalian adenylyl cyclases" *Ann. Rev. Pharm. Tox.* 36: 461-480 (1996).

- 15 Takahashi, T., et al. "Rat brain serotonin receptors in *Xenopus* oocytes are coupled by intracellular calcium to endogenous channels" *Proc. Natl. Acad. Sci. USA* 84: 5063-5067 (1987).

- 20 Tanaka, K., Masu, M., Nakanishi, S. "Structure and functional expression of the cloned rat neurotensin receptor" *Neuron* 4: 847-854 (1990).

Tian, W., et al. "Determinants of alpha-Adrenergic Receptor Activation of G protein: Evidence for a Precoupled Receptor/G protein State" *Mol. Pharmacol.* 45: 524-553 (1994).

- 25 Watling, K.J. "The RBI Handbook of Receptor Classification and Signal Transduction" Sigma-Aldrich Research Biochemicals Inc., Natick, MA (1998).